System and method for determining the concentration of an analyte in a sample fluid

Description

TECHNICAL FIELD OF THE INVENTION

The present invention relates to a measurement method and apparatus for use in measuring concentrations of an analyte in a fluid. The invention relates more particularly, but not exclusively, to a method and apparatus which may be used for measuring the concentration of glucose in blood.

BACKGROUND OF THE INVENTION

Measuring the concentration of substances, particularly in the presence of other, confounding substances, is important in many fields, and especially in medical diagnosis. For example, the measurement of glucose in body fluids, such as blood, is crucial to the effective treatment of diabetes.

Diabetic therapy typically involves two types of insulin treatment: basal and bolus. Basal insulin refers to continuous, e.g. time-released insulin. Bolus insulin treatment provides additional doses of faster acting insulin to regulate fluctuations in blood glucose caused by a variety of factors, including the meal-time metabolization of sugars and carbohydrates, etc. Proper regulation of blood glucose fluctuations requires accurate measurement of the concentration of glucose in the blood. Failure to do so can produce extreme complications, including blindness or impaired circulation in the extremities, which can ultimately deprive the diabetic of use of his or her fingers, hands, feet, etc.

Multiple methods are known for measuring the concentration of analytes in a blood sample, such as, for example, glucose. Such methods typically fall into one of two categories: optical methods and electrochemical methods. Optical methods generally involve reflectance or absorbance spectroscopy to observe the spectrum shift in a reagent. Such shifts are caused by a chemical reaction that produces a color change indicative of the concentration of the analyte. Electrochemical methods generally involve, alternatively, amperometric or coulometric responses indicative of the concentration of the analyte. See, for example, U.S. Pat. Nos. 4,233,029 to Columbus, 4,225,410 to Pace, 4,323,536 to Columbus, 4,008,448 to Muggli, 4,654,197 to Lilja et al., 5,108,564 to Szuminsky et al., 5,120,420 to Nankai et al., 5,128,015 to Szuminsky et al., 5,243,516 to White, 5,437,999 to Diebold et al., 5,288,636 to Pollmann et al., 5,628,890 to Carter et al., 5,682,884 to Hill et al., 5,727,548 to Hill et al., 5,997,817 to Crismore et al., 6,004,441 to Fujiwara et al., 4,919,770 to Priedel, et al., 6,054,039 to Shieh, and 6,645,368 to Beaty et al., which are hereby incorporated by reference in their entireties.

For the convenience of the user, reducing the time required to display an indication of the glucose level in a blood sample has been a goal of system designers for many years. Test times have been reduced from early colorimetric products that took approximately two minutes to display a reading, to test times on the order of 20-40 seconds. More recently, test times shorter than ten seconds have been described (see, for example, U.S. Pat. Nos. 7,276,146 and 7,276,147), and several products currently on the market advertise test times of about five seconds. Shorter test times of less than two seconds have been discussed in various patent applications (see, for example, U.S. Patent Application Publication Nos. 2003/0116447A1 and 2004/0031682A1). But the true utility of a short test time is not completely reached with these teachings in terms of the results being substantially unaffected by confounding interferents.

An important limitation of electrochemical methods for measuring the concentration of a chemical in blood is the effect of confounding variables on the diffusion of analyte and the various active ingredients of the reagent. Examples of limitations to the accuracy of blood glucose measurements include variations in blood composition or state (other than the aspect being measured). For example, variations in hematocrit (concentration of red blood cells), or in the concentration of other chemicals in the blood, can effect the signal generation of a blood sample. Variations in the temperature of the blood samples is yet another example of a confounding variable in measuring blood chemistry. The utility of a reported blood glucose response after a short test time is questionable in applications where the results are not compensated for other sample variables or interferents such as hematocrit and temperature.

With respect to hematocrit in blood samples, prior art methods have relied upon the separation of the red blood cells from the plasma in the sample, by means of glass fiber filters or with reagent films that contain pore-formers that allow only plasma to enter the films, for example. Separation of red blood cells with a glass fiber filter increases the size of the blood sample required for the measurement, which is contrary to test meter customer expectations. Porous films are only partially effective in reducing the hematocrit effect, and must be used in combination with increased delay time and/or AC measurements (see below) to achieve the desired accuracy.

Prior art methods have also attempted to reduce or eliminate hematocrit interference by using DC measurements that include longer incubation time of the sample upon the test strip reagent, thereby reducing the magnitude of the effect of sample hematocrit on the measured glucose values. Such methods also suffer from greatly increased test times.

Other attempts to reduce or eliminate hematocrit and temperature interference are taught in U.S. Pat. No. 7,407,811, as well as in the disclosures of the parent cases to this application, in which an AC potential of a low amplitude is applied to a sample in order to determine certain sample characteristics based on phase angle (also referred to herein as “phase”) and admittance information from the current response to the AC excitation signal. As it is taught, multiple frequencies of an AC excitation signal are applied in sequential blocks, followed by a conventional DC excitation signal. However, those disclosures indicate the inventors' belief that there are limits to the minimum time each frequency must be applied in order to obtain useful, consistent and reasonably reproducible information, from both the AC and DC excitation signals. Even then, the shortest total test time practically achievable from a complete AC method was 3 seconds. Alternatively, to achieve a practical analysis in less than 3 seconds, a limit was placed on the number of frequency blocks used during the AC excitation, i.e. 2 blocks rather than 4. However, reducing the number of frequency blocks used may have a negative affect on the level of accuracy attainable in correcting for multiple interferents, e.g., hematocrit and temperature. As has been taught in these previous disclosures of AC excitation, correction of the indicated glucose can be achieved for multiple interferents by obtaining multiple correction factors, such as the phase and/or admittance response data resulting from multiple frequencies of an AC signal excitation. Multiple correction factors are particularly beneficial when they measure individual or different aspects of interferents or when they are influenced by one interferent more than the other.

Furthermore, the correction factors or even the measurements used for determining the desired analyte concentration may also be used for calculating and optionally reporting additional parameters such as the hematocrit level or hematocrit range of the blood. By reducing the number of potential correction factors, e.g. measuring the phase and/or admittance from only two rather than three, four or more frequencies of an AC excitation, potentially useful information could be forsaken. Information such as hematocrit level or hematocrit range, for example, could be useful information for a user, especially for health care providers in a clinical setting where patients who are more susceptible to medically significant abnormal hematocrits due to illness or treatment could be identified during a routine blood glucose test. Providing a hematocrit level, for example, in addition to the glucose concentration would be a valuable piece of information in some settings, which could be lost as a result of the solutions presented by the prior art.

Thus, a system and method are needed that more accurately measure blood glucose, even in the presence of confounding variables, including variations in hematocrit, temperature and the concentrations of other chemicals in the blood. Further needed are such system and method with test times of less than 2 seconds. A system and method are likewise needed that accurately measure any medically significant component of any biological fluid with test times of less than 2 seconds. It is an object of the present invention to provide such a system and method.

SUMMARY OF THE DISCLOSED EMBODIMENTS

In one embodiment, a method for determining a concentration of a medically significant component of a biological fluid is disclosed, comprising the steps of: applying a first signal having an AC component to the biological fluid; measuring a first current response to the first signal; applying a second signal comprising a DC signal to the biological fluid; measuring a second current response to the second signal; combining the first and second responses; and determining an indication of the concentration of the medically significant component. In other embodiments, the time for completing the steps is no more than about 2 seconds. In yet other embodiments, the Total System Error from the method is no more than about 10%. In yet other embodiments, the first signal comprises an AC signal comprising a multi-frequency excitation waveform wherein different AC frequencies are generally simultaneously applied rather than sequentially applied in order to minimize the time for completing application of the first and second signals.

Other embodiments of a system and method will be understood from the description herein and as set forth in the claims appended hereto.

BRIEF DESCRIPTION OF THE DRAWINGS

The invention will be further described, by way of example only, with reference to the accompanying drawings, in which:

FIG. 1 is a plot of current versus time for measurements using a biosensor having a reagent layer thickness of about 3.6 μm, parameterized for time between sample application and application of the DC excitation.

FIG. 2 is a table showing the glucose, hematocrit and temperature levels used in a first covariate study described herein.

FIG. 3 tabularly illustrates the excitation signal profile and timing for a first study described herein.

FIG. 4 graphically illustrates the excitation signal profile and timing for a first study described herein.

FIG. 5 is a graph of normalized error versus reference glucose for uncorrected measurement data from a first study described herein.

FIG. 6 is a graph of normalized error versus reference glucose for the data of FIG. 5 corrected using the methods described herein.

FIG. 7 is a plot of current versus time for measurements using a biosensor having a reagent layer thickness of about 1.6 μm, parameterized for time between sample application and application of the DC excitation.

FIG. 8 is a plot of admittance versus time showing stabilization of the AC response in a first study described herein.

FIG. 9 is a plot showing the cross-sectional thickness of the biosensor reagent stripe in a first study described herein.

FIG. 10 is a table showing the glucose, hematocrit and temperature levels of whole blood samples used in a first study described herein.

FIG. 11 illustrates the excitation signal profile and timing used for a second study described herein.

FIG. 12 is a table showing the measurement performance of three reagent thicknesses used in a second study described herein.

FIG. 13 is a plot of normalized error versus reference glucose level for a second study described herein.

FIG. 14 is a Clark Error Grid showing predicted glucose versus reference glucose for the uncorrected DC data obtained in a second study described herein.

FIG. 15 is a Clark Error Grid showing predicted glucose versus reference glucose for the DC data of FIG. 14 corrected using AC measurement data.

FIG. 16 is a plot of one embodiment multi-sine excitation waveform used in a third study described herein.

FIG. 17A is a table of 200 ms admittance and phase response data for a third covariate blood glucose measurement study obtained using the methods disclosed herein.

FIG. 17B is a graph of admittance magnitude versus hematocrit from the data table of FIG. 17A.

FIG. 17C is a graph of phase versus hematocrit from the data table of FIG. 17A.

FIG. 18 is a table showing both uncorrected blood glucose measurement evaluations at several test times, as well as measurement evaluations for the same data corrected using the methods disclosed herein, in a third study described herein.

FIG. 19 is a graph of normalized error versus reference glucose for uncorrected measurement data from a third study described herein.

FIG. 20 is a graph of normalized error versus reference glucose for the data of FIG. 19 corrected using the methods disclosed herein.

FIG. 21 is a Clark Error Grid showing predicted glucose versus reference glucose for both the uncorrected data of FIG. 19 and the corrected data of FIG. 20.

FIG. 22 is a table showing both uncorrected blood glucose measurement evaluations at several test times, as well as measurement evaluations for the same data corrected using the methods disclosed herein, in a fourth study described herein.

FIG. 23 is a graph of normalized error versus reference glucose for uncorrected measurement data from a fourth study described herein.

FIG. 24 is a graph of normalized error versus reference glucose for the data of FIG. 23 corrected using the methods disclosed herein.

FIG. 25 is a Clark Error Grid showing predicted glucose versus reference glucose for both the uncorrected data of FIG. 23 and the corrected data of FIG. 24.

FIG. 26 is a table showing target versus actual values for the results of the fourth covariate study described herein.

FIG. 27 is a graph of admittance magnitude versus hematocrit from the fourth covariate study described herein.

FIG. 28 is a graph of phase versus hematocrit from the fourth covariate study described herein.

FIG. 29 is an exemplary current response resulting from a measurement sequence comprising a multi-frequency AC excitation waveform followed by a DC excitation, performed on a whole blood sample having a target glucose concentration of 93 mg/dL and 70% hematocrit.

FIG. 30 is a table of estimated and measured dry coating film thickness according to coat weight in a known wet reagent application process.

FIG. 31 is a graph of admittance magnitude versus hematocrit from the fifth covariate study described herein.

FIG. 32 is a graph of DC current response measured at different test times and co-varied by hematocrit.

FIG. 33. is a graph of normalized error versus reference glucose for uncorrected DC measurement data measured at 900 ms, from the fifth study described herein.

FIG. 34 is a graph of normalized error versus reference glucose for DC measurement data measured at 900 ms and corrected according to the fifth study described herein.

FIG. 35 is a graph of normalized error versus reference glucose for DC measurement data measured at 1100 ms and corrected according to the fifth study described herein.

FIG. 36 is a graph of normalized error versus reference glucose for DC measurement data measured at 1500 ms and corrected according to the fifth study described herein.

FIG. 37 is a graph of normalized error versus reference glucose for DC measurement data measured at 2000 ms and corrected according to the fifth study described herein.

FIG. 38 is a graph of normalized error versus reference glucose for DC measurement data measured at 2500 ms and corrected according to the fifth study described herein.

FIG. 39 is a graph of normalized error versus reference glucose for DC measurement data measured at 3000 ms and corrected according to the fifth study described herein.

FIG. 40 is a table showing TSE for corrected responses at the different DC test times corrected according to the fifth study described herein.

FIG. 41 is a Clark Error Grid showing predicted glucose versus reference glucose for the uncorrected DC response data at 900 ms according to the fifth study described herein.

FIG. 42 is a Clark Error Grid showing predicted glucose versus reference glucose for the DC response data at 900 ms corrected by response data from one AC frequency, according to the fifth study described herein.

FIG. 43 is a Clark Error Grid showing predicted glucose versus reference glucose for the DC response data at 900 ms corrected by response data from another AC frequency, according to the fifth study described herein.

FIG. 44 is a Clark Error Grid showing predicted glucose versus reference glucose for the DC response data at 900 ms corrected by response data from two AC frequencies, according to the fifth study described herein.

DETAILED DESCRIPTION OF THE VARIOUS EMBODIMENTS

For the purposes of promoting an understanding of the principles of the invention, reference will now be made to the embodiments illustrated in the drawings, and specific language will be used to describe those embodiments. It will nevertheless be understood that no limitation of the scope of the invention is intended. Alterations and modifications in the illustrated device, and further applications of the principles of the invention as illustrated therein, as would normally occur to one skilled in the art to which the invention relates are contemplated and are desired to be protected. In particular, although the invention is discussed in terms of a blood glucose test device and measurement methods, it is contemplated that the invention can be used with devices for measuring other analytes and other sample types. Such alternative embodiments require certain adaptations to the embodiments discussed herein that would be obvious to those skilled in the art.

A system and method according to the present invention permit the accurate measurement of an analyte in a fluid in an ultra-fast test time, namely no more than about 2 seconds. In particular, the measurement of the analyte remains accurate despite the presence of interferents, which would otherwise cause error. For example, a blood glucose meter according to the present invention measures the concentration of blood glucose within whole blood samples without error that is typically caused by variations in the hematocrit level of the sample and the temperature of the sample. The accurate measurement of blood glucose is invaluable to the prevention of blindness, loss of circulation, and other complications of inadequate regulation of blood glucose in diabetics. An additional advantage of a system and method according to the present invention is that measurements can be made much more rapidly and with much smaller sample volumes, making it more convenient for the diabetic person to measure their blood glucose. Likewise, accurate and rapid measurement of other analytes in blood, urine, or other biological fluids provides for improved diagnosis and treatment of a wide range of medical conditions.

It will be appreciated that electrochemical blood glucose meters typically (but not always) measure the electrochemical response of a blood sample in the presence of a reagent. The reagent reacts with the glucose to produce charge carriers that are not otherwise present in blood. Consequently, the electrochemical response of the blood in the presence of a given signal is intended to be primarily dependent upon the concentration of blood glucose. Secondarily, however, the electrochemical response of the blood to a given signal may be dependent upon other factors, including hematocrit and temperature. See, for example, U.S. Pat. Nos. 5,243,516; 5,288,636; 5,352,351; 5,385,846; and 5,508,171, which discuss the confounding effects of hematocrit on the measurement of blood glucose, and which are hereby incorporated by reference in their entireties. In addition, certain other chemicals can influence the transfer of charge carriers through a blood sample, including, for example, uric acid, bilirubin, and oxygen, thereby causing error in the measurement of glucose.

The various embodiments disclosed herein relate to systems and methods that allow shorter test times to be achieved, while still delivering an analyte measurement (be it blood glucose or another fluid sample analyte) corrected for confounding interferents (be they hematocrit and temperature, or other interferents). Test times of less than two seconds, including times less than one second, are enabled by the systems and methods disclosed herein. As used herein, “Total Test Time” is defined as the length of time from sample detection (or sample dose sufficiency, if both are detected) when a first electrical signal is to be applied to the sample, to the taking of the last measurement used in the concentration determination calculations.

In addition to shorter Total Test Times, the embodiments disclosed herein result in analyte measurements having lower Total System Error, or “TSE”. TSE generally comprises a combined measure of accuracy and precision of a system or method. It is typically calculated as (Absolute Bias)+2*(Precision), where Bias=Average of Normalized Error; Precision=StdDev(Normalized Error). Normalized Error is typically calculated relative to a standard reference value. For example, in the context of a blood glucose measurement, Normalized Error=(Predicted glucose−Reference glucose) for a Reference glucose sample less than or equal to 75 mg/dl; but Normalized Error=(Predicted glucose−Reference glucose)*100/(Reference glucose) for a Reference glucose sample greater than 75 mg/dl.

As used herein, the phrase “a signal having an AC component” refers to a signal which has some alternating potential (voltage) portions. For example, the signal may be an “AC signal” having 100% alternating potential (voltage) and no DC portions; the signal may have AC and DC portions separated in time; or the signal may be AC with a DC offset (AC and DC signals superimposed). In the latter instance, the signal may still be described as having an AC component even though the polarity of the variable potential does not alternate.

Examples 1 and 2 describe details of experiments in which Total Test Time was reduced. In each example, an AC block is used in order to generate correction data to be combined algorithmically with a DC measurement, similar to the known measurement sequence utilized in the ACCU-CHEK® Aviva meter. That is, multiple AC potential frequencies are applied in a sequential fashion with current response and other measurement data determined for each frequency. However, in Examples 1 and 2, the Total Test Time is reduced by reducing the time for each sequential AC frequency block, as well as the time for the DC block. Example 1 details an experiment using these condensed time blocks in a covariate study, using a biosensor with a common reagent layer thickness. Example 2 details an experiment with the condensed times in a covariate study using biosensors having variable reagent layer thicknesses.

Measurement sequences for Examples 1 and 2 were conducted using an in-house data acquisition test stand (DATS potentiostat) comprising a bank of blood glucose meters configured as a multi-meter test stand using a modified code key to program desired measurement parameters. Although the meters could be programmed or configured with a variety of methods and durations for a test sequence, there were a few limitations, such as the choice of frequencies available pre-programmed in the meter hardware. This in-house test stand will be hereinafter referred to as the “DATS”.

Certain embodiments of the present invention disclosed herein generally utilize the collection of AC test data at multiple frequencies over a shorter time period by using multi-frequency excitation waveform techniques. Examples 3 and 4 describe the details of experiments in which multi-frequency excitation waveforms were used. These multi-frequency excitation waveforms are formed by adding a plurality of individual waveforms of varying frequency together so that the fluid sample is excited by multiple frequencies at the same time. Multi-frequency excitation waveforms allow not only short measurement times, but also adaptive measurement sequences, because AC signal data collection does not permanently alter the sensed chemistry in the way that a DC measurement does because of the alternating polarity of the applied excitation. Moreover, the additional frequencies of the AC signals are applied at low excitation AC potentials, per the methods disclosed in co-pending published U.S. patent applications US-2004-0157339-A1, US-2004-0157337-A1, 2004/0157338-A1, US-2004-0260511-A1, US-2004-0256248-A1 and US-2004-0259180-A1, in order to generate a non-faradaic current response from which a phase angle provides an indication of certain interfering factors, from which indication a determination of one or more interferent corrections can be made and used for more accurately determining the analyte concentration in the fluid sample.

The resulting sample response can then be measured and the contribution from each excitation frequency component can be deduced by use of Fourier Transform techniques, such as a Discrete Fourier Transform (DFT). Although the various examples disclosed herein utilize multi-sine excitation waveforms, those skilled in the art will recognize that the multi-frequency waveform may be constructed using individual waveforms having any desired shape, such as triangular, square, sawtooth, delta, etc., just to name a few non-limiting examples. The component AC waveforms used to create the multi-frequency waveform may each have any desired frequency and any desired amplitude. The use of multi-frequency techniques not only shortens the time necessary to collect the desired data (since the AC measurements are made simultaneously rather than sequentially), but also correlates better for correction since the sample is varying less during the data collection corresponding to each applied frequency. Also, the AC measurement can be made closer in time to the DC measurement. Better correlation between the state of the sample during the respective AC and DC measurements allows for better interferent compensation even if the sample is not in steady state.

Measurements for Examples 3 and 4 were conducted with an electrochemical test stand constructed on the basis of VXI components from Agilent, and programmable to apply AC and DC potentials to sensors in requested combinations and sequences and to measure the resulting current responses of the sensors. Data were transferred from the electrochemical analyzer to a desktop computer for analysis using Microsoft® Excel®. The measurements could be carried out by any commercially available programmable potentiostat with an appropriate frequency response analyzer and digital signal acquisition system. For commercial use, the method can be carried out in a dedicated low-cost hand-held measurement device, such as the ACCU-CHEK® AVIVA™ blood glucose meter, in which the firmware is configured to enable application of AC signals in a multi-frequency waveform. In such a case the measurement parameters may be contained in or provided to the firmware of the meter, and the measurement sequence and data evaluation executed automatically with no user interaction. For example, using a programmable potentiostat as described above, measurements were conducted and results analyzed in a manner such that Total Test Times of less than 2 seconds after the analyte-containing sample was applied to a biosensor and detected by the equipment are possible. Similarly, the firmware of the ACCU-CHEK® AVIVA™ blood glucose meter may be provided with measurement parameters configured and arranged to cause the measurement sequence to occur within the same time periods, namely Total Test Times of less than 2 seconds after the analyte-containing sample is applied to a biosensor and detected by the meter. The measurement result may be displayed on the digital display of the meter when the evaluation of the measurement data is complete, typically 25-50 ms after the last measurement is taken.

EXAMPLE 1
Sequential Multiple AC Frequency Test with Fast Total Test Time

U.S. Pat. No. 7,407,811 teaches use of sequentially applied multiple frequency AC blocks followed by a DC block. For example, Example 5 described in U.S. Pat. No. 7,407,811 utilizes sequential applications of AC excitation followed by a DC excitation. The excitation signal comprised a 10 kHz AC signal applied for approximately 1.8 seconds, a 20 kHz AC signal applied for approximately 0.2 seconds, a 2 kHz AC signal applied for approximately 0.2 seconds, a 1 kHz AC signal applied for approximately 0.2 seconds, and a DC signal applied for approximately 0.5 seconds. The Total Test Time was 3.0 seconds.

In Example 6 of that same patent, it was desired to obtain Total Test Times as low as 1.1 seconds using the same test strip design that was used for Example 5 in that patent. In order to achieve this, the inventors did not believe that they could simply apply the sequential excitations of Example 5 for shorter periods of time. As stated in the patent:

- “Using the same test strip 1700 and reagent described above for Example 5, the excitation profile illustrated in FIG. 24 was utilized in order to decrease the Total Test Time. As described above with respect to Example 5, it was determined that the phase angle at 20 kHz and at 10 kHz were most closely correlated with the hematocrit estimation. It was therefore decided to limit the AC portion of the excitation to these two frequencies in Example 6 in order to decrease the Total Test Time. In order to make further reductions in Total Test Time, the 10 kHz AC excitation was applied simultaneously with the DC signal (i.e. an AC signal with a DC offset), the theory being that this combined mode would allow for the collection of simultaneous results for DC current, AC phase and AC admittance, providing the fastest possible results. Therefore, the 20 kHz signal was applied for 0.9 seconds. Thereafter, the 10 kHz and DC signals were applied simultaneously for 1.0 second after a 0.1 second interval.”
  
  (U.S. Pat. No. 7,407,811, col. 23, 11. 23-40). The inventors of U.S. Pat. No. 7,407,811 therefore believed that in order to shorten the Total Test Time below 3.0 seconds, they needed to remove two of the AC excitation blocks (those at 2 kHz and 1 kHz) and apply one of the remaining two AC excitation blocks concurrently with the DC excitation.

One reason for this belief in the prior art is illustrated in FIGS. 1 and 7, where the measured DC response of a sample applied to the reagent chemistry is shown for various tests where the timing of the application of the DC excitation signal after sample application is varied. It can be seen that when the DC excitation is applied very quickly after sample application, the response does not exhibit the expected Cottrellian decay, thereby making accurate determinations of the sample glucose concentration impossible for fast test times. This is because enzyme and mediator availability, hydration, and diffusion within the reagent layer limit how soon the DC measurement can be made in a reproducible fashion. Reagent hydration and coating uniformity from sensor to sensor is a significant factor in how fast the DC response can be measured.

We have found that shorter AC times are possible because information to correlate with interferences such as hematocrit is presented in the AC response data even at early times. Although there is some stabilization of AC over the first few 100 ms, the signals for AC even at short times correlate well with the hematocrit interference. Using information for all desired frequencies gathered at the same interval from the desired glucose DC response enables good correlation or correction of the DC glucose response with the AC measured hematocrit interference.

The present Example 1 was conducted to demonstrate the feasibility of running the prior art sequential multiple AC frequency test methodology at a faster rate using sensors slot die coated with a uniform reagent formulation containing glucose oxidase. (Slot die coating of uniform reagents are described in U.S. Patent Application Publication No. 2005/0008537, which is incorporated herein by reference in its entirety). The sensor electrodes were made by the process of gold sputtering (˜50 ηm) onto Melinex 329 followed by laser ablation through a chrome-on-quartz mask to form the pattern of the conductive layer to define the working and dose sufficiency electrodes. The structures used were similar to that shown in U.S. Pat. No. 7,407,811, at FIG. 33. The electrodes included a pair of dose sufficiency electrodes independent of a pair of measurement electrodes. Measurements were made using the DATS. A benefit of the DATS configuration is the ease of setup and fast, multi-channel data collection in environmental chambers at different temperatures. Using a DATS comprising existing meters configured for use with AC excitation measurement methods did present some limitations in terms of programmability including specific transition times required between blocks and also the available AC frequencies, essentially all basic, non-programmable aspects of the meters used with the DATS. However, using such existing meters was useful in that the sequential multiple AC frequency method examined in Example 1 (and in Example 2, below) could be backwardly compatible for use with the existing meters.

A covariate study was performed with whole blood samples having seven different glucose target concentrations (50, 100, 150, 250, 300, 450 and 550 mg/dL), three different hematocrit target concentrations (25%, 45% and 70%) and five different temperatures (8, 14, 24, 35 and 42 degrees C.). The table of FIG. 2 details the whole blood sample compositions used for this Example 1.

AC data was collected using sequentially applied AC excitation signals of 10 kHz, 20 kHz, 2 kHz and 1 kHz at 9 mV RMS. Then, after a 100 ms open circuit, a DC potential of 450 mV was applied starting at 1300 ms. DC measurement data was collected every 100 ms starting at 1400 ms, and the 1525 ms DC data point was analyzed in this Example 1 (i.e. the tests utilized a Total Test Time of 1.525 seconds). (DC data points were taken at times later than the Total Test Time in order to confirm the viability of the shorter Total Test Time. Because the viability of a Total Test Time at, e.g., 1.525 seconds or less was confirmed, the DC data points at longer times were not used for calculating final results.) The table of FIG. 3 tabulates the excitation signal composition and timing, while this data is presented graphically in a general way in FIG. 4.

FIG. 5 plots the normalized error versus the reference glucose for approximately 1600 data points for all 105 covariant samples ([G], % HCT, ° C.), using only the uncorrected DC measurement taken at 1525 ms. Determining the predicted glucose from the DC measurement was performed using well known prior art techniques. As will be readily apparent to those skilled in the art, the performance of the measurement system with such a short DC-only test time is extremely poor, with a Total System Error of 51%.

As shown in FIGS. 3 and 4, the AC excitation potentials (1 through 5) for this Example 1 were applied sequentially. The sequence described was started after a 10 kHz signal was first applied (not shown) to detect sample application (dose detection) and the filling of the capillary test chamber (sample sufficiency) determination. The use of AC measurements for drop detect and dose sufficiency is described in U.S. Pat. No. 7,597,793, which is hereby incorporated herein by reference.

After the sample sufficiency determination, a 300 ms 10 kHz block was applied for AC stabilization, followed by four additional AC data blocks each of 100 ms duration at 10 kHz, 20 kHz, 2 kHz and 1 kHz signals. All times herein are started in relation to detection of sample dose sufficiency. Furthermore, Block 1 was kept in the sequence of FIG. 3 mainly for backward compatibility to an ACCU-CHEK® AVIVA™-related meter failsafe, which is not relevant to the present invention. In addition, Block 1 was used to stabilize the AC prior to the next block at the same frequency. One of the goals of some of this work was to show a backwards compatible short test time for the product platform of ACCU-CHEK® AVIVA™ meters. Additional experiments were conducted with only two frequencies to examine the limits of the effectiveness of correction in sequential AC/DC vs. test time. See, e.g. FIG. 8.

After the AC measurements, the measurement electrodes were then held at an open circuit for 100 ms, followed by application of a 450 mV DC signal. Between each excitation block, there was a 75 ms delay consisting of a 50 ms pre-stabilization and a 25 ms trailing data communication period. Test times were evaluated at 1525 ms (Test Time=1.525 seconds uses DC at 1.5 sec+0.025 s communication time)

AC admittance values were captured for each of the four 100 ms AC excitation blocks in order to correct the DC glucose measurement for the interfering effects of hematocrit and temperature using the following equation:

Predicted Glucose=INT+Yi2*Y2+Pi2*P2+Yi3*Y3+Pi3*P3+Yi4*Y4+Pi4*P4+Yi5*Y5+Pi5*P5+exp(SLOPE+Ys2*Y2+Ps2*P2+Ys3*Y3+Ps3*P3+Ys4*Y4+Ps4*P4+Ys5*Y5+Ps5*P5)*DC**POWER (equation 1)

where: Yi2, Yi3, Yi4, Yi5, Ys2, Ys3, Ys4 and Ys5 are constants

Pi2, Pi3, Pi4, Pi5, Ps2, Ps3, Ps4 and Ps5 are constants

Y2 is the admittance magnitude at 10 kHz (second block)

Y3 is the admittance magnitude at 20 kHz

Y4 is the admittance magnitude at 2 kHz

Y5 is the admittance magnitude at 1 kHz

P2 is the phase angle at 10 kHz (second block)

P3 is the phase angle at 20 kHz

P4 is the phase angle at 2 kHz

P5 is the phase angle at 1 kHz

INT is the intercept

SLOPE is the slope

DC is the uncorrected glucose response predicted with the DC measurement

POWER=Const+Yp2*Y2+Pp2*P2+Yp3*Y3+Pp3*P3+Yp4*Y4+Pp4*P4+Yp5*Y5+Pp5*P5

Equation 1 demonstrates that the system's dose-response can be approximated by a power model. The slope and power of this power model are influenced by covariates such as temperature and hematocrit. Since the AC measurements (admittance and phase) are sensitive to these covariates, they are used in the slope and power terms to compensate for the covariate effects. The parameter estimates are established by parameter estimation with data collected where glucose, temperature and hematocrit are covaried. The DC value in this example was selected from one measured DC point, and Equation 1 is specific to a single DC value. For more DC values, i.e. more than one current response measurement taken during the DC block, a more general representation is:

Predicted Glucose=ba0+a1*Ieff+a2*Peff+a3*Yeff+(b4+exp(b0+b2*Peff+b3*Yeff))*Ieff**(c0+c2*Peff+c3*Yeff)
where: Ieff=bV0+bV1*DC1+bV2*DC2+bV3*DC3+bV4*D4+bV5*DC5+bV6*DC6
Peff=bP0+bP1*P1+bP2*P2+bP3*P3+bP4*P4+bP5*P5+bP6*P6
Yeff=bY0+bY1*Y1+bY2*Y2+bY3*Y3+bY4*Y4+bY5*Y5+bY6*Y6

The use of AC admittance magnitude and phase data to correct DC glucose response data for the effects of hematocrit and temperature is discussed in detail in U.S. Pat. No. 7,407,811.

Like FIG. 5, FIG. 6 also plots the normalized error versus the reference glucose for all 105 samples, except that the DC measurement taken at 1525 ms has been corrected using the AC measurements and the methodology discussed hereinabove. Such correction allows the measurement system to compensate for the interfering effects of hematocrit and temperature. As can be seen, all measurement results now fall with +/−15% normalized error, with a total system error of 9.4%, all with a test time of only 1.525 seconds.

This Example 1 therefore demonstrates that an extremely short test time of 1.525 seconds can be achieved using multiple serial AC excitation frequencies in order to probe the sample and measure interferents that prevent accurate assessment of the glucose value, and to correct the measured glucose value to remove the effects of these interferents upon the measurement. This surprising result is in contravention to the teachings of the prior art as pointed out above.

Control of Reagent Thickness

Some of the embodiments disclosed herein, including embodiments shown from the description of Example 2 below, also utilize accurate control of the biosensor reagent thickness through the use of a uniform method of applying the reagent to the biosensor surface, such as by slot die coating, for example. The reagent coatings disclosed herein are generally about 1.6-5 μm in thickness. The uniformity of the reagent coating, and thus the resulting uniform dissolution/hydration of the reagent film with the fluid sample, enables reproducibility that correlates well with the AC measurements to provide accurately compensated glucose. Non-uniform reagent thicknesses are detrimental to achieving faster methods and improved performance because of more variability in the measurements, especially at short times. For robust performance, we strive for a very uniform film. For a description of methods and disclosure relating to coating uniform films, see U.S. Patent Application Publication No. 2005/0008537, referred to above.

FIG. 1 and FIG. 7 illustrate the measured DC response of a sample applied to the reagent chemistry for various tests where the timing of the application of the DC excitation signal after sample application is varied from about 75 ms to 1400 ms. Hydration of FIG. 1 is less uniform strip to strip than the thinner reagent in FIG. 7. Applying the DC excitation too soon after sample application can result in non-Cottrellian responses and therefore inaccurate glucose concentration measurements.

Using coating methods as generally described in U.S. Patent Application Publication No. 2005/0008537, the reagent coating for FIG. 1 (50 g/m²coat weight) was approximately 3.6 μm and for FIG. 7 (20 g/m²coat weight) was approximately 1.6 μm. It can be seen that when the DC excitation is applied very quickly after sample application to the thinner reagent layer, the response begins to exhibit the expected Cottrellian-like decay characteristics much more quickly, thereby making accurate determinations of the sample glucose concentration possible for fast test times. This is because enzyme availability, hydration, and diffusion within the reagent layer, which limit how soon the DC measurement can be made, are improved with the thinner and or more uniform reagent layer thickness. FIG. 30 shows a table of coat weight settings and the estimated and actual measured dry coating film thicknesses, using wet reagent coating methods described in the U.S. 2005/0008537 publication. The equipment operating parameters required to achieve each coat weight will be appreciated from that publication and ordinary skill in the art in that regard.

Technology and methodologies useful for forming thin reagent strips on biosensors are disclosed in U.S. Patent Application Publication Nos. 2005/0016844 and 2005/0008537, the disclosures of which are hereby incorporated by reference herein in their entireties.

FIG. 8 summarizes tests performed on biosensors having a reagent coating formed thereon at thicknesses of 4 μm, 2.5 μm and 2.0 μm. Table 1 shows the general formulation of the wet reagent coated on the biosensors used in FIG. 8. The reagent was similar to that of ACCU-CHEK® AVIVA™ biosensors, but prepared with a milled silica. Milled silica was used to reduce the mean particle size of the silica due to concerns that the unmilled silica may have particle sizes that would be detrimental to thinner coatings. They were coated at different coat weights leading to different measured thicknesses. The goal was to start with a reagent mass for glucose biosensors that had some previous optimization at least for the upper thickness level. Then a slot die coating method was used to prepare reagent thicknesses from about 4 μm to 2 μm by adjusting the coat weight using the same reagent mass. By making the reagents in this manner, the concentrations of the active ingredients that were initially optimized for the thicker coat weight are also reduced.

TABLE 1

Wet Reagent

% w/w

Keltrol F
0.22%

CMC
0.57%

Sipernat FK320 DS (milled)
2.02%

PVP K25
1.91%

Propiofan
2.88%

GlucDOR wt
0.40%

PQQ
0.01%

Na-Succinate
0.29%

Trehalose
0.48%

KH₂PO₄
0.39%

K₂HPO₄× 3H₂O
1.19%

Mediator 31.1144
0.93%

Mega 8
0.28%

Geropon T77
0.03%

KOH
0.14%

Water total
88.27%

Sum
100.00%

Blood samples were applied to each of the biosensors and AC excitation frequencies of either 2 kHz or 20 kHz were applied to the biosensors as the reagent was hydrated with the sample. Admittance data was measured every 100 ms for one second and plotted in FIG. 8. As can be seen, the AC admittance has stabilized in less than 400 ms after sample application, and the AC data at 100 ms was shown to be adequate for use in correcting the resultant DC glucose test using the procedure disclosed hereinbelow. From the data represented in FIGS. 1 and 7, it is clear that thin reagents stabilize quite fast after sample application. Of the films tested, the thinner reagents gave AC responses that stabilized faster and in a more reproducible manner

The ability to achieve fast test times as disclosed herein is greatly influenced by the rate of hydration of the enzyme and mediator in the reagent film, and the rate of diffusion of the reaction products to the electrode surface under the reagent film. The use of the slot die coating methodologies for deposition of reagent layers disclosed in U.S. Patent Application Publication Nos. 2005/0016844 and 2005/0008537 allows deposition of uniformly thin film reagents for faster and more reproducible dissolution of reagents, fill times and hydration profiles. FIG. 9 shows a surface profilometry measurement of a thin film reagent deposited on a biosensor using these methods to a target thickness of 2.5 μm (nominal coat weight=30 g/m²). As can be seen, the mean thickness in the central B region of the reagent strip is 2.46 μm. Enzyme availability, hydration, and diffusion are faster and more uniformly behaved with thin reagent films (in one embodiment, approximately 1.6-10 μm in thickness, and in other embodiments, approximately 1.6-5 μm in thickness).

Thin films benefit measurements in terms of faster hydration that permits measuring sooner after sample application. The AC stabilization appears to be less affected by film thickness than the DC response. A more Cottrellian-like behavior is observed in response to DC excitation at earlier times when the films are thinner. This can be seen by comparison of FIG. 1 and FIG. 7. FIG. 1 shows current responses for thicker films, i.e. 50 g/m², which as illustrated give variable early I vs. T traces when DC excitation is started around 100-700 ms after sample sufficiency is detected. In contrast, as shown in FIG. 7, the current responses follow a nice trend for the 20 g/m²for the same time range. In addition, the I vs. T response becomes more Cottrellian-like at about 300 ms after applying the DC potential. There are some limitations that need to be considered with regard to thin films, however. There is a minimum amount of enzyme needed on the sensor both for obtaining a linear response and maintaining the required long-term stability of the sensor. The films in this example, because they were made from the same reagent mass, had proportionally less enzyme as they were made thinner. The lower limit of film thickness generally depends on the concentration of enzymes in the reagent mass to provide adequate response and stability. It is also understood that there would be some lower limit of thickness where the coating methods and variability of the thickness of the substrate would not provide a uniform coating thickness. For other issues and disclosure relating to control of uniform and homogeneous film thickness, see, e.g., U.S. Patent Application Publication No. 2005/0008537 referred to hereinabove.

EXAMPLE 2
Sequential Multiple AC Frequency Test with Fast Total Test Time and Varying Reagent Thickness

A covariate study testing multiple whole blood samples for glucose concentration was performed using the electrode and testing structures similar to the ACCU-CHEK® AVIVA™ biosensor available from Roche Diagnostics, Inc. of Indianapolis, Ind. USA. A pyrroloquinoline quinone dependent glucose dehydrogenase (PQQ-GDH) based reagent with the same or substantially similar formulation from Table 1 (above) was applied to the biosensors in one of three thicknesses: 2 μm, 2.5 μm and 4 μm. A covariate study was performed with whole blood samples similar to Example 1 but with six glucose concentrations, five hematocrit levels, and five temperatures, as detailed in FIG. 10.

The AC excitation potentials for this Example 2 were applied sequentially as detailed in FIG. 11. A 10 kHz dose detection and sample sufficiency method (not shown) was followed by a 300 ms 20 kHz signal followed by 100 ms applications of 20 kHz, 10 kHz, 2 kHz and 1 kHz signals. The measurement electrodes were then held at an open circuit for 100 ms, followed by application of a 550 mV DC signal. Because of the pre-set timing parameters in the existing meters of the DATS, there was a 50 ms stabilization delay and a 25 ms trailing data communication period between each excitation block. Measurements of the response to the DC signal were extracted at Total Test Times starting at about 1500 ms, and measured at 100 ms intervals. AC admittance values were captured for each of the AC excitation blocks in order to correct the DC glucose measurement for the interfering effects of hematocrit and temperature using the following equation:

Predicted Glucose=INT+Yi2*Y2+Pi2*P2+Yi3*Y3+Pi3*P3+Yi4*Y4+Pi4*P4+Yi5*Y5+Pi5*P5+exp(SLOPE+Ys2*Y2+Ps2*P2+Ys3*Y3+Ps3*P3+Ys4*Y4+Ps4*P4+Ys5*Y5+Ps5*P5)*DC**POWER (equation 2)

where: Yi2, Yi3, Yi4, Yi5, Ys2, Ys3, Ys4 and Ys5 are constants

Pi2, Pi3, Pi4, Pi5, Ps2, Ps3, Ps4 and Ps5 are constants

Y2 is the admittance magnitude at 20 kHz (second block)

Y3 is the admittance magnitude at 10 kHz

Y4 is the admittance magnitude at 2 kHz

Y5 is the admittance magnitude at 1 kHz

P2 is the phase angle at 20 kHz (second block)

P3 is the phase angle at 10 kHz

P4 is the phase angle at 2 kHz

P5 is the phase angle at 1 kHz

INT is the intercept

SLOPE is the slope

DC is the uncorrected glucose response predicted with the DC measurement

POWER=Const+Yp2*Y2+Pp2*P2+Yp3*Y3+Pp3*P3+Yp4*Y4+Pp4*P4+Yp5*Y5+Pp5*P5

It will be appreciated that Equation 2 is substantially the same as Equation 1 from Example 1. The primary difference is only in the sequence order of applying the different frequencies, wherein the Example 1 applied frequency sequence was 10-20-2-1 kHz, and the Example 2 applied frequency sequence was 20-10-2-1 kHz.

As referred to above, Total System Error, or TSE, is a combined measure of accuracy and precision of the system. It is typically defined as: (Absolute Bias)+2*(Precision). The details are as follows:

Bias=Average of Normalized Error;

Precision=StdDev(Normalized Error);

where

Normalized Error=(Predicted Glucose−Reference Glucose) when Reference Glucose<=75 mg/dl; and

Normalized Error=(Predicted Glucose−Reference Glucose)*100/(Reference Glucose) when Reference Glucose>75 mg/dl.

FIG. 13 plots the normalized error versus the reference glucose value for the DC measurement data corrected using the AC measurements as detailed hereinabove. Only the DC measurement taken at 1500 ms was used (+25 ms for communications), therefore this data represents a realistic total test time of 1.525 seconds. The interfering effects of the hematocrit and temperature have been substantially reduced, with a Total System Error of 10.0% for the entire covariate study.

FIG. 14 is a Clark Error Grid showing the predicted glucose value versus reference glucose value for all of the uncorrected DC glucose measurements taken at 1525 ms. The Clarke Error Grid Analysis (EGA) was developed in 1987 to quantify the clinical accuracy of patient estimates of their current blood glucose as compared to the blood glucose value obtained in their meter. See Clarke W L, Cox D, Gonder-Frederick L A, Carter W, Pohl S L: Evaluating clinical accuracy of systems for self-monitoring of blood glucose. Diabetes Care 10:622-628, 1987. The Clark Error Grid has since been used to quantify the clinical accuracy of blood glucose estimates generated by test meters as compared to a reference value. The EGA is generally accepted as a standard methodology for determining the accuracy of blood glucose meters.

The Clark Error Grid breaks down a scatter plot of test results from a reference glucose meter and an evaluated glucose meter into five regions. Region A are those values within 20% of the reference sensor, Region B contains points that are outside of 20% but would not lead to inappropriate treatment, Region C are those points leading to unnecessary treatment, Region D are those points indicating a potentially dangerous failure to detect hypoglycemia, and Region E are those points that would confuse treatment of hypoglycemia for hyperglycemia and vice-versa. In FIG. 14, the dashed lines additionally indicate values within 15% of the reference sensor.

As can be readily seen in FIG. 14, the uncorrected glucose values fall well outside the +/−15% error window, which is the desired error window set forth in a Clark Error Grid. This level of accuracy would be considered to be unacceptable in a glucose test meter according to general industry practice for blood glucose monitoring systems, as well as according to FDA guidelines.

FIG. 15 is a Clark Error Grid showing the same DC test data shown in FIG. 14, except that the data has been corrected for the interfering effects of hematocrit and temperature using the methodology described hereinabove. As can be readily seen in FIG. 15, the performance of the measurement system when corrected for hematocrit and temperature using the AC measurement data is far superior to using only the DC measurement results to predict the glucose values at extremely fast Total Test Times.

As can be seen from the above Example 2, the use of thin reagent films, such as about 1.6-5 μm in thickness supports the ability to perform accurate glucose determinations, corrected for the interfering effects of hematocrit and temperature, with Total Test Times below 2 seconds. The uniformity of the reagent coating, and thus the resulting uniform dissolution/hydration of the reagent film with the fluid sample, is believed to enable reproducibility that correlates well with the AC measurements to provide accurately compensated glucose test results.

From Examples 1 and 2, it has become clear that, despite the previous understanding in the art, shorter test times can be achieved by shortened sequential AC blocks and/or by use of fewer sequential AC frequencies. However, using more frequencies can provide benefits in measurement correction, especially when correcting for multiple variables or when desired to actually provide an indication of the level or general range of one or more such variables in addition to the analyte measurement. In order to accomplish this, and still achieve the shortest possible test, the use of multi-frequency excitation waveforms was explored, such as set forth in Examples 3 and 4.

Multi-Frequency Excitation

As noted herein, some of the embodiments disclosed herein utilize the collection of AC test data at multiple frequencies over a shorter time period by using multi-frequency excitation waveform techniques. These multi-frequency excitation waveforms are formed by adding a plurality of individual waveforms of varying frequency together so that the fluid sample is excited by multiple frequencies substantially simultaneously, rather than sequentially.

The resulting sample response can then be measured and this measurement will contain the sample response to all of the excitation frequencies. The specific contribution from each excitation frequency component can be then deduced by use of Fourier Transform techniques, such as a Discrete Fourier Transform (DFT). Although the various examples disclosed herein utilize multi-sine excitation waveforms, those skilled in the art will recognize that the multi-frequency waveform may be constructed using individual waveforms having any desired shape, such as triangular, square, sawtooth, delta, etc., just to name a few non-limiting examples. The component AC waveforms used to create the multi-frequency waveform may each have any desired frequency and any desired amplitude. The use of multi-frequency techniques not only shortens the time necessary to collect the desired data (since the AC measurements are made simultaneously rather than sequentially), but also correlates better for correction since the sample is varying less during the data collection corresponding to each applied frequency. This is particularly true for tests utilizing a very fast Total Test Time, where the measurements are made very shortly after sample application and the sample is still undergoing diffusion and reaction with the reagent chemistry. Also, the AC measurement can be made closer in time to the DC measurement. Better correlation between the AC and DC allows for better interferent compensation even if the sample is not in steady state.

An exemplary prior art measurement sequence for a blood glucose testing system that corrects for the interfering effects of hematocrit and temperature, such as those disclosed in U.S. Pat. No. 7,407,811, is as follows:

Step 1: Blood is applied to a biosensor in a meter.
Step 2: AC measurements are taken of the sample for drop detect and/or dose sufficiency.
Step 3: AC measurements are taken over a period of time to allow calculation of correction factors for hematocrit and temperature. In many instances, multiple AC excitation frequencies are applied to the sample sequentially.
Step 4: DC measurements are taken to measure the raw (uncorrected) glucose response.
Step 5: The raw DC response is compensated for hematocrit and temperature effects using the AC measurement-derived correction factors.
Step 6: Measurement result is displayed to the user.

This procedure has some drawbacks with respect to obtaining a measurement result in less than 2 seconds. While accurate measurement results may be obtained by correcting the raw DC glucose measurement with the AC-derived data on hematocrit and temperature, the additional time required to collect the AC data lengthens the total test time and also separates in time the various AC and DC measurements that are used to arrive at the final measurement result. This separation in time of the various AC and DC measurements can be of some concern in some situations since the sample under test continues to undergo chemical reactions with the reagents and the reagents are being hydrated during this time. That is, in a measurement sequence in which an AC signal is applied with different waveform frequencies sequentially, the admittance and phase data for each frequency, while still useful for the correction of the subsequent raw DC response measurement, is not ideal because each data point is taken at a different time during the progression of the sample-reagent hydration-reaction dynamics. By applying all frequencies simultaneously within the AC excitation waveform, the admittance and phase data for each frequency is still separately discernible and advantageously relates to the same state of the sample-reagent dynamics.

A current response measured from application of an exemplary multi-frequency AC excitation waveform followed by application of a DC signal is illustrated in FIG. 29. For Examples 3 and 4, data acquisition was conducted using an electrochemical test stand constructed on the basis of VXI components from Agilent, and programmable to apply AC and DC potentials to sensors in requested combinations and sequences and to measure the resulting current responses of the sensors.

EXAMPLE 3
Multi-Frequency AC Test with Fast Total Test Time

The measurements conducted for Example 3 were made with electrode structures similar to that of ACCU-CHEK® AVIVA™ biosensors and reagents the same or similar to the formulation set forth in Table 1 (above). These sensors were fabricated using generally the same technology as ACCU-CHEK® AVIVA™ biosensors using a combination of processes including sputtering, laser ablation, reagent slot die coating, and lamination.

The measurement sequence consisted of three basic blocks. The first measurement block (not shown) utilized a 10240 Hz sine wave excitation applied to the test strips in order to detect sample dose sufficiency (filling of the capillary test chamber sufficient to conduct a measurement). The use of AC measurements for drop detect and dose sufficiency is described in U.S. Pat. No. 7,597,793, referred to hereinabove.

After sufficient sample was detected, the second measurement block was begun using a multi-sine (also known as polyphonic) waveform for a short time interval (as detailed below) to simultaneously collect AC admittance magnitude and phase data for each frequency of interest. The multi-sine waveform used for this Example 3 was constructed by summing sine waves of four frequencies (1024, 2048, 10240 and 20480 Hz). These frequencies were selected because they are known to be useful for correction of interferents, according to Applicants' prior disclosures regarding use of AC excitation which are referred to hereinabove. The higher frequency ranges of about 20 and about 10 kHz are known to provide useful correction for hematocrit. The lower frequency ranges of about 1 and about 2 kHz were included because of the known potential for useful discrete measurements. Generally, this combination of frequencies allow for correction of multiple parameters such as hematocrit and temperature. It is well understood that these values do not have to be specifically 20 kHz, for example, but only in a range where the interferents can be measured reasonably independent of the glucose response which is to be corrected. A higher frequency may correlate more with one interferent such as hematocrit, whereas another frequency may correlate more with another interferent. Optimization of the frequency or combination of frequencies that would provide the best overall correction response would be useful, and is well within the skill of a person of ordinary skill in the art in view of this disclosure. However, in working with multi-frequency AC waveforms to reduce the time to collect response data from multiple frequencies while still providing good correction and short total test times, it was decided that using the frequencies in these known ranges would be useful in order to rely on past experience. In addition, previous experience shows that data from more than one frequency can correct for multiple interferents better than measuring at only one frequency. Four frequencies were chosen here so that previously programmed data analysis routines could be used. However, two, three or even five or more frequencies, for example, may just as well supply adequate correction. Some discrete AC methods with only two AC frequencies have been conducted.

For Example 3, the multi-sine waveform consisted of one period of the 1024 Hz signal, two periods of the 2048 Hz signal, 10 periods of the 10240 Hz signal, and 20 periods of the 20480 Hz signal. The peak amplitude was set at 12.7 mV, but due to the multi-sine nature of the signal, the actual RMS value would be significantly lower. (RMS is the root mean square value of the waveform SQRT[(1/N)*SUM(x²)].) The waveform comprised 16000 data points that were input to a digital-to-analog converter and is illustrated in FIG. 16.

One benefit of using the multi-sine excitation waveform is that the AC measurement time required to collect data for all four frequencies is reduced because the measurements are made simultaneously. Another benefit of the multi-sine excitation waveform is that the AC measurement data for all of the frequencies is collected simultaneously and is thus less affected by the fact that the sample is changing as it reacts with the reagent.

The multi-sine waveform was applied to the test sample for 300 ms after an indication of dose sufficiency and analyzed in 100 ms intervals. Although this Example 3 utilized a 300 ms measurement period, longer, shorter and even variable time periods may be employed with similar results. Generally, to achieve a Total Test Time of two seconds or less, the range for the multi-sine measurement period in one embodiment is 100 ms to 1900 ms. With the ACCU-CHEK® AVIVA™ test structures used, 200-500 ms was a sufficient period to give reproducible AC responses from the test sample.

Although the various excitation frequencies are applied to the sample simultaneously using the multi-sine signal, the responses attributable to each frequency component can be extracted from the AC measurement data using an appropriate mathematical function, such as a Fast Fourier Transform (FFT) or a Discrete Fourier Transform (DFT) or other mathematical techniques, as will be appreciated by those skilled in the art. Admittance magnitude and phase data for each frequency was extracted in the present Example 3 using DFT. This extracted admittance data for each frequency is shown in FIG. 17A for the time point correlating to 200 ms after dose sufficiency for all nine samples tested. A graph of phase to hematocrit at each frequency for Example 3 is illustrated in FIG. 17B, and a graph of admittance magnitude to hematocrit at each frequency for Example 3 is illustrated in FIG. 17C.

The second measurement block consisted of a 550 mV DC signal applied to the sample in order to obtain a raw (uncorrected) predicted glucose reading, as is known in the art. Four DC time points were extracted from the measurement data as 100 ms average data points with ending data points at 500, 600, 1000 and 1500 ms (i.e. for Total Test Times of 0.5, 0.6, 1.0 and 1.5 seconds).

Nine whole blood samples were prepared for a covariate study using target glucose concentrations of 90, 250 and 600 mg/dL and target hematocrit values of 20, 45 and 70%. For each sample tested, each DC time point was analyzed by nonlinear fit and the 300 ms AC admittance magnitude and phase data was used to calculate the predicted glucose response compensated for the effects of hematocrit and temperature using the following equation:

Predicted Glucose=INT+Yi1*Y1+Pi1*P1+Yi2*Y2+Pi2*P2+Yi3*Y3+Pi3*P3+Yi4*Y4+Pi4*P4+exp(SLOPE+Ys1*Y1+Ps1*P1+Ys2*Y2+Ps2*P2+Ys3*Y3+Ps3*P3+Ys4*Y4+Ps4*P4)*DC**POWER (equation 3)

where: Yi1, Yi2, Yi3, Yi4, Ys1, Ys2, Ys3 and Ys4 are constants

Pi1, Pi2, Pi3, Pi4, Ps1, Ps2, Ps3 and Ps4 are constants

Y1 is the admittance magnitude at 1024 Hz

Y2 is the admittance magnitude at 2048 Hz

Y3 is the admittance magnitude at 10240 Hz

Y4 is the admittance magnitude at 20480 Hz

P1 is the phase angle at 1024 Hz

P2 is the phase angle at 2048 Hz

P3 is the phase angle at 10240 Hz

P4 is the phase angle at 20480 Hz

INT is the intercept

SLOPE is the slope

DC is the uncorrected glucose response predicted with the DC measurement

POWER is=Const+Yp1*Y1+Pp1*P1+Yp2*Y2+Pp2*P2+Yp3*Y3+Pp3*P3+Yp4*Y4+Pp4*P4.

Again this equation is the same form as Equations 1 and 2, but as can be seen the variables range from Y1 to Y4 and P1 to P4 for the simultaneous AC at 200 ms, rather than Y2-Y5 and P2-P5 which are used in Equations 1 and 2.

As discussed above, the use of AC admittance magnitude and phase data to correct DC glucose response data for the effects of hematocrit and temperature is discussed in U.S. Pat. No. 7,407,811.

The uncorrected glucose response from the DC measurement (i.e. uncorrected for the interfering effects of hematocrit and temperature) was determined using well-known prior art techniques. This DC glucose response was then corrected for the interfering effects of hematocrit and temperature using the AC admittance magnitude and phase measurement data as detailed above in equation 3. The Total System Error (TSE), bias, precision and NVar were calculated for each Total Test Time (for both corrected and uncorrected results) and these are tabulated in FIG. 18. As can be readily seen, the performance of the measurement system when corrected for hematocrit and temperature using the AC measurement data is far superior to using only the DC measurement results to predict the glucose values. Furthermore, acquiring the AC measurement data simultaneously for multiple excitation frequencies permits extremely fast Total Test Times with measurement results exhibiting very good TSE values for Total Test Times of 1.5 seconds, 1.0 second, 0.6 seconds and 0.5 seconds.

FIG. 19 plots the normalized error versus the reference glucose value for the uncorrected glucose measurements, and a significant dependence on the hematocrit value can be seen in the data. The Total System Error is 53.8%. FIG. 20 plots the normalized error versus the reference glucose value for the same measurements, only this time the DC measurement data has been corrected using the AC measurement as detailed hereinabove. The interfering effect of the hematocrit has clearly been substantially reduced, with a Total System Error of 14.2%. This reduction was achieved using only the AC measurement data taken at 500 ms after the dose sufficiency indication.

FIG. 21 is a Clark Error Grid showing the predicted glucose value versus reference glucose value for all of the above 500 ms data points, both corrected and uncorrected. As can be readily seen, the uncorrected glucose values fall well outside the +/−15% error window, while the corrected data are all within this limit. Therefore, the use of multi-frequency excitation to achieve a one-half second glucose Total Test Time was demonstrated.

The above data of this Example 3 clearly shows that the use of the multi-frequency excitation techniques disclosed herein allow extremely short test times by allowing the sample to be simultaneously excited by multiple frequencies and the sample responses to those frequencies to be simultaneously measured. Even at one-half second Total Test Times, the data provides a significant reduction in the DC measurement error caused by interferents, and allows essentially instantaneous measurement results to be reported to the user with a measurement accuracy well within accepted industry standards.

EXAMPLE 4
Multi-Frequency AC Test with Fast Total Test Time

The measurements conducted for Example 4 were made with the same electrode structures and reagents as Example 3 and the same measurement sequencing. However, whereas the Example 3 measurements were performed on samples having three different target analyte concentrations and three different hematocrit levels for each concentration, the Example 4 measurements were performed on samples having seven different target analyte concentrations and three hematocrit levels for each concentration.

As was found in Example 3, it was learned from the measurements of Example 4 that a benefit of using the multi-sine excitation waveform is that the AC measurement time required to collect data for all four frequencies is reduced because the measurements are made simultaneously. Another benefit of the multi-sine excitation waveform is that the AC measurement data for all of the frequencies is collected simultaneously and is thus less affected by the fact that the sample is changing as it reacts with the reagent.

Twenty-one whole blood samples were prepared for a covariate study using target glucose concentrations of 50, 100, 140, 250, 300, 450 and 550 mg/dL and target hematocrit values of 20, 45 and 70%. For each sample tested, each DC time point was analyzed by nonlinear fit and the 300 ms AC admittance magnitude and phase data was used to calculate the predicted glucose response compensated for the effects of hematocrit and temperature using the following equation:

Predicted Glucose=INT+Yi1*Y1+Pi1*P1+Yi2*Y2+Pi2*P2+Yi3*Y3+Pi3*P3+Yi4*Y4+Pi4*P4+exp(SLOPE+Ys1*Y1+Ps1*P1+Ys2*Y2+Ps2*P2+Ys3*Y3+Ps3*P3+Ys4*Y4+Ps4*P4)*DC**POWER (equation 4)

where: Yi1, Yi2, Yi3, Yi4, Ys1, Ys2, Ys3 and Ys4 are constants

Pi1, Pi2, Pi3, Pi4, Ps1, Ps2, Ps3 and Ps4 are constants

Y1 is the admittance magnitude at 1024 Hz

Y2 is the admittance magnitude at 2048 Hz

Y3 is the admittance magnitude at 10240 Hz

Y4 is the admittance magnitude at 20480 Hz

P1 is the phase angle at 1024 Hz

P2 is the phase angle at 2048 Hz

P3 is the phase angle at 10240 Hz

P4 is the phase angle at 20480 Hz

INT is the intercept

SLOPE is the slope

DC is the uncorrected glucose response predicted with the DC measurement

POWER is=Const+Yp1*Y1+Pp1*P1+Yp2*Y2+Pp2*P2+Yp3*Y3+Pp3*P3+Yp4*Y4+Pp4*P4.

Again, Equation 4 is the same form as Equations 1 and 2, but as with Equation 3 from Example 3, one can see that the variables range from Y1 to Y4 and P1 to P4 for the simultaneous AC at 200 ms, rather than Y2-Y5 and P2-P5 which are used in Equations 1 and 2.

As discussed in Example 3, the use of AC admittance magnitude and phase data to correct DC glucose response data for the effects of hematocrit and temperature is discussed in U.S. Pat. No. 7,407,811. A graph of admittance magnitude to hematocrit at each frequency for Example 4 is illustrated in FIG. 27, and a graph of phase to hematocrit at each frequency for Example 4 is illustrated in FIG. 28.

The uncorrected glucose response from the DC measurement (i.e. uncorrected for the interfering effects of hematocrit and temperature) was determined using well-known prior art techniques. This DC glucose response was then corrected for the interfering effects of hematocrit and temperature using the AC admittance magnitude and phase measurement data as detailed above in equation 4. The Total System Error (TSE), bias, precision and NVar were calculated for each Total Test Time (for both corrected and uncorrected results) and these are tabulated in FIG. 22. As can be readily seen, the performance of the measurement system when corrected for hematocrit and temperature using the AC measurement data is far superior to using only the DC measurement results to predict the glucose values. Furthermore, acquiring the AC measurement data simultaneously for multiple excitation frequencies permits extremely fast Total Test Times. As shown in FIG. 22, measurement results exhibit very good TSE values at Total Test Times of 1.525 seconds, 1.025 seconds, 0.725 seconds and 0.625 seconds.

FIG. 23 plots the normalized error versus the reference glucose value for the uncorrected glucose measurements, and a significant dependence on the hematocrit value can be seen in the data. The Total System Error is 47.5%. FIG. 24 plots the normalized error versus the reference glucose value for the same measurements, only this time the DC measurement data has been corrected using the AC measurement as detailed hereinabove. The interfering effect of the hematocrit has clearly been substantially reduced, with a Total System Error of 10.2%. The measurement data for each of the 21 measurement runs can be seen in FIG. 26.

FIG. 25 is a Clark Error Grid showing the predicted glucose value versus reference glucose value for all of the 725 ms data points, both corrected and uncorrected. As can be readily seen, most of the uncorrected glucose values fall well outside the +/−15% error window, while the corrected data are all within this limit. Therefore, the use of multi-frequency excitation to achieve a less than three-quarters of a second glucose Total Test Time was demonstrated.

The above data of this Example 4 clearly shows that the use of the multi-frequency excitation techniques disclosed herein allow extremely short test times by allowing the sample to be simultaneously excited by multiple frequencies and the sample responses to those frequencies to be simultaneously measured. Even at sub-three-quarter second Total Test Times, the data provides a significant reduction in the DC measurement error caused by interferents, and allows essentially instantaneous measurement results to be reported to the user with a measurement accuracy well within accepted industry standards.

EXAMPLE 5
Sequential Multiple AC Frequency Test with Fast Total Test Time at Various DC Time Points

This Example 5 was conducted similarly to Example 2 (above), using test sensors having a reagent film thickness based on a nominal 30 g/m²coat weight application which, as shown in FIG. 30, corresponds approximately to a thickness of 2.45 μm. Unlike Example 2, however, data acquisition was conducted using an electrochemical test stand constructed on the basis of VXI components from Agilent, and programmable to apply AC and DC potentials to sensors in requested combinations and sequences and to measure the resulting current responses of the sensors. This was done because, as noted with regard to Examples 1 and 2, the existing meters used with the DATS for those measurements comprise pre-set parameters in which mandatory time blocks are required for a preceding waveform stabilization, trailing communication after each frequency block, and a pre-set “skip” period in the initial 100 ms of DC signal application during which no current response can be measured. For this Example 5, however, it was desired to apply sequential multiple AC frequencies without the limitations of the pre-set timing conditions imposed by the existing meters of the DATS. The Agilent-based test stand used for Example 3 and 4 provided the flexibility to program a desired measurement sequence in this way.

The purpose of Example 5 was to explore different ways in which a set of four short 200 ms AC excitation blocks applied sequentially and having frequencies of 20, 2, 10, and 1 kHz can be used to correct a DC glucose response, co-varied with hematocrit, at a single generally uniform reagent film thickness. The AC excitation blocks were applied starting at a time zero, which is the time at which sufficient sample dosing is detected. Thus, the AC excitation blocks begin at time zero with no open period in between, ending at about 800 ms, at which time the DC excitation was applied.

The DC response data was collected starting at 800 ms through 3700 ms. This dataset was used to analyze the data with varying AC and DC parameters. The goal was to determine if good performance could be reached with this uniform thin film at short test times, and to determine the effect of using one or multiple AC responses for the corrections. FIG. 31 shows the AC response vs. hematocrit for the 4 AC frequencies measured. All of these data show an inverse relationship of admittance response to increased hematocrit. As can be seen, the measurements at the higher frequencies of 20 kHz and 10 kHz exhibit generally similar responses, and the measurements at the lower frequencies of 2 kHz and 1 kHz exhibit generally similar responses. However, the higher frequencies have a greater hematocrit vs. admittance relationship.

FIG. 32 shows uncorrected DC response data collected for this covariate study and it is clear that at each DC test time there are variable current responses associated with the varied hematocrit levels. FIG. 33 shows a typical response of an uncorrected Normalized Error to a referenced glucose value for the covariant study using the DC response measured at 900 ms. The uncorrected response has a TSE of 41%. However, as shown in FIG. 34, when the DC response at 900 ms is corrected using the AC response data from just two frequencies, namely 20 kHz and 2 kHz, there is significant improvement of the TSE, which has decreased to 7.1%. FIGS. 35-39 show Normalized Error plots for the corrected DC response measured at 1100 ms, 1500 ms, 2000 ms, 2500 ms, and 3000 ms, respectively, again corrected using only the AC response data from the 20 kHz and 2 kHz sequentially applied frequencies of the AC signal.

FIG. 40 shows a table of the TSE according to variable DC test time for DC response data corrected in two ways, first with the 20 kHz and 2 kHz AC response data and second with the 10 kHz and 1 kHz AC response data. The AC response data at 20 kHz and 2 kHz provided a better correction for this test configuration (in terms of TSE) than the 10 kHz and 1 kHz response data.

FIG. 40 also indicates that at a short test time of 900 ms the TSE is actually better than at longer times; that is, there is an increase in TSE as the DC measurement time increases, but this is then followed by a decrease in TSE at the much longer time of 3000 ms. It is believed that the TSE is lower at the shorter DC measurement times because at the shorter DC measurement times the time between measurement of the AC responses (for obtaining the correction factors) and the measurement of the DC response (for obtaining analyte-related data) is on the order of only 100-900 ms. That is, the AC response data is obtained approximately at times 200 ms, 400 ms, 600 ms and 800 ms, with the shorter DC response data being obtained at 900 and 1100 ms. Thus, the correction factor responses and the analyte response correlate best when film hydration and reaction properties are almost identical. At shorter DC response measurement times measurements are made closer to the electrode surface with short diffusion distances where there is less effect due to film hydration and swelling.

As measurements are made at moderately longer DC response times, the TSE increases because the AC correction factors and the DC response are further apart (less correlated) because the film is hydrating and swelling rapidly and the DC response is being measured in this region of rapid change. However at even longer DC measurement times, e.g. 3000 ms, the TSE comes back down when the reagent hydration and swelling begins to stabilize, causing the DC value to have less variability and needing less correction by the AC correction factors. Thus, at these longer measurement times, the TSE appears to improve to values close to the TSE of the earlier DC response measurement time. Typically, AC/DC responses taught in prior art disclosures measured the DC response data when the DC response was most stable, which is typically later, and thus lost some of the correlation between correction factors and analyte response. Here we show that we can measure the DC response at earlier measurement times and still obtain an acceptable analyte response with the added benefit of reduced test time. In the case of this Example 5, the Total Test Time is less than 1 second (i.e. 900 ms).

It is also believed that the AC correction factors disclosed herein correct not just the hematocrit affects but also other sources of error or variability of the reagent film state. In the examples described herein, the electrodes used to detect the AC signal response are the same ones used for the DC signal response, and thus are coated with the reagent film. As a result, all AC response measurements are affected by the state of the reagent film with liquid sample applied (e.g. thickness, swelling).

Another way to look at these data is from corresponding Clark Error Grids. FIG. 41 shows the Error Grid for the uncorrected DC response data at a 900 ms DC measurement time. FIGS. 42-44 show the same 900 ms DC measurement data corrected with AC response data for only 20 kHz (FIG. 42), only 2 kHz (FIG. 43), and both 20 kHz and 2 kHz (FIG. 44).

The data from Example 5 supports a finding that an analyte measurement having good TSE can be achieved at short Total Test Times, between 900 ms and 3000 ms.

Example 5 was not co-varied with temperature as was done in Example 2 because the electrochemical test stand was less conducive to running “environmental” studies. Thus, the AC signal responses or correction factors determined from those responses in this example do not contain information on sample temperature variations and correction as was shown in Example 2. However, AC methods using the 4 AC frequencies have been shown to correct both hematocrit and temperature variations, and the measurement method of Example 5 would be sufficient to do this with a test time of less than 1000 ms.

For purposes of the examples disclosed herein, the DC excitation applied is described and shown generally as a single block of applied potential for a single duration. DC response data may be taken throughout that duration or only at one or only a few points in that duration. Not shown or described, however, is a DC excitation application which comprises two or more shorter pulses of DC excitation with response data measured for each such pulse. While none of the examples herein illustrate the use of this type of DC excitation, it is believed that the AC waveforms described herein, both sequential and multi-frequency (simultaneous) waveforms, can correct the response data obtained from the pulsed type of DC excitation.

The features disclosed in the above description, the claims and the drawings may be important both individually and in any combination with one another for implementing the invention in its various embodiments.

It is noted that terms like “preferably”, “commonly”, and “typically” are not utilized herein to limit the scope of the claimed invention or to imply that certain features are critical, essential, or even important to the structure or function of the claimed invention. Rather, these terms are merely intended to highlight alternative or additional features that may or may not be utilized in a particular embodiment of the present invention.

For the purposes of describing and defining the present invention it is noted that the term “substantially” is utilized herein to represent the inherent degree of uncertainty that may be attributed to any quantitative comparison, value, measurement, or other representation. The term “substantially” is also utilized herein to represent the degree by which a quantitative representation may vary from a stated reference without resulting in a change in the basic function of the subject matter at issue.

Having described the present invention in detail and by reference to specific embodiments thereof, it will be apparent that modification and variations are possible without departing from the scope of the present invention defined in the appended claims. More specifically, although some aspects of the present invention are identified herein as preferred or particularly advantageous, it is contemplated that the present invention is not necessarily limited to these preferred aspects of the present invention.

Claims

1. A method for determining a concentration of an analyte of interest in a biological sample, comprising: a) applying a first signal having a first AC component to the sample;b) measuring a first response to the first signal;c) applying a second signal having a second AC component to the sample;d) measuring a second response to the second signal;e) applying a third signal having a third AC component to the sample;f) measuring a third response to the third signal;g) applying a fourth DC signal to the sample;h) measuring a fourth response to the fourth DC signal; ande) determining the analyte concentration of the sample using at least the first, second and third responses to correct the fourth response for the effects of at least one interferent within the sample, wherein the determination has a Total Test Time of within about 2.0 seconds or less, and wherein the first, second third, and fourth signals are applied to the sample during separate time periods;wherein the first signal is applied for no more than about 100 ms before the first response is measured;wherein the second signal is applied for no more than about 100 ms before the second response is measured;wherein the third signal is applied for no more than about 100 ms before the third response is measured; andwherein the fourth signal is applied for no more than about 200 ms before the fourth response is measured.
2. The method of claim 1, wherein the determination has a Total Test Time of between about 0.5 seconds and about 1.525 seconds.
3. The method of claim 1, wherein the method has a Total System Error of less than about 11%.
4. The method of claim 1, wherein the biological sample is blood and the analyte of interest is glucose.
5. The method of claim 1, wherein the first, second and third signals each comprise an AC signal, each AC signal having a different frequency, and wherein the fourth signal comprises a DC signal.
6. The method of claim 1, wherein the interferent comprises one or both of hematocrit and temperature.
7. The method of claim 1, further comprising: applying a fifth signal having a fourth AC component to the sample during a separate time period from the first, second, third and fourth signals; andmeasuring a fifth response to the fifth signal;wherein said determination of the analyte concentration of the sample uses at least the first, second, third and fifth responses to correct the fourth response for the effects of at least one interferent within the sample; andwherein the fifth signal is applied for no more than about 100 ms before the fifth response is measured.
8. The method of claim 7, wherein the first, second, third and fifth signals each comprise an AC signal, each AC signal having a different frequency, and wherein the fourth signal comprises a DC signal.
9. The method of claim 7, wherein the first signal is a 10 kHz AC signal, the second signal is a 20 kHz AC signal, the third signal is a 1 kHz AC signal, and the fifth signal is a 2 kHz AC signal.
10. The method of claim 7, wherein the fourth signal is applied for no more than about 200 ms before the fourth response is measured.
11. The method of claim 7, wherein the method has a Total System Error of less than about 11%.
12. The method of claim 11, wherein the method has a Total System Error of between about 7.5% and about 11%.

REFERENCE TO RELATED APPLICATIONS

This application is a divisional application of U.S. Utility application Ser. No. 13/418,611, filed Mar. 13, 2012, now U.S. Pat. No. 8,298,828. U.S. patent application Ser. No. 13/418,611 is a divisional application of U.S. Utility patent application Ser. No. 12/650,065, filed Dec. 30, 2009, now issued as U.S. Pat. No. 8,148,164, issued Apr. 3, 2012. U.S. Utility patent application Ser. No. 12/650,065 is a continuation-in-part of U.S. Utility patent application Ser. No. 10/871,966, filed Jun. 18, 2004, now issued as U.S. Pat. No. 7,749,437, issued Jul. 6, 2010, which claims the benefit of U.S. Provisional Application No. 60/480,397, filed Jun. 20, 2003. U.S. Utility patent application Ser. No. 12/650,065 is also a continuation-in-part of U.S. Utility patent application Ser. No. 10/871,673, filed Jun. 18, 2004, now issued as U.S. Pat. No. 7,727,467, issued Jun. 1, 2010, which claims the benefit of U.S. Provisional Application No. 60/480,397, filed Jun. 20, 2003. U.S. Utility patent application Ser. No. 12/650,065 is also a continuation-in-part of U.S. Utility patent application Ser. No. 12/505,124, filed Jul. 17, 2009, which is a divisional of U.S. Utility patent application Ser. No. 12/330,757, filed Dec. 9, 2008, now issued as U.S. Pat. No. 7,977,112, issued Jul. 12, 2011, which is a continuation of U.S. Utility patent application Ser. No. 10/688,561, filed Oct. 17, 2003, now issued as U.S. Pat. No. 7,488,601, issued Feb. 10, 2009, which claims the benefit of U.S. Provisional Application No. 60/480,298, filed Jun. 20, 2003. U.S. Utility patent application Ser. No. 12/650,065 is also a continuation-in-part of U.S. Utility patent application Ser. No. 11/746,465, filed May 9, 2007, which is a continuation-in-part of U.S. patent application Ser. No. 10/688,312, now issued as U.S. Pat. No. 7,390,667, issued Jun. 24, 2008. The contents of these applications and patents are hereby incorporated by reference in their entirety.

US Referenced Citations (725)

Number	Name	Date	Kind
286735	Rossler	Oct 1883	A
672094	Cliffton	Apr 1901	A
2526651	Garbo	Aug 1945	A
2883169	Daman	Apr 1959	A
3526480	Findl et al.	Sep 1970	A
3551295	Dyer	Dec 1970	A
3621381	Eckfeldt	Nov 1971	A
3656543	Wolowodiuk et al.	Apr 1972	A
3661748	Blackmer	May 1972	A
3715192	Wenz et al.	Feb 1973	A
3720093	Gill	Mar 1973	A
3763422	MacPhee et al.	Oct 1973	A
3770607	Williams	Nov 1973	A
3776832	Oswin et al.	Dec 1973	A
3838033	Mindt et al.	Sep 1974	A
3870099	Wolowodiuk	Mar 1975	A
3902970	Levin	Sep 1975	A
3919627	Allen	Nov 1975	A
3922598	Steuer et al.	Nov 1975	A
3925183	Oswin et al.	Dec 1975	A
3937615	Clack et al.	Feb 1976	A
3980437	Kishimoto et al.	Sep 1976	A
4005002	Racine et al.	Jan 1977	A
4008448	Muggli	Feb 1977	A
4040908	Clark, Jr.	Aug 1977	A
4053381	Hamblen et al.	Oct 1977	A
4060127	Savin et al.	Nov 1977	A
4065263	Woodbridge, III	Dec 1977	A
4086631	Vick	Apr 1978	A
4123701	Josefsen et al.	Oct 1978	A
4127448	Schick et al.	Nov 1978	A
4184936	Paul et al.	Jan 1980	A
4214968	Battaglia et al.	Jul 1980	A
4217196	Huch	Aug 1980	A
4224125	Nakamura et al.	Sep 1980	A
4225410	Pace	Sep 1980	A
4230537	Delente et al.	Oct 1980	A
4233029	Columbus	Nov 1980	A
4260680	Muramatsu et al.	Apr 1981	A
4263343	Kim	Apr 1981	A
4265250	Parker	May 1981	A
4273134	Ricciardelli	Jun 1981	A
4273639	Gottermeier	Jun 1981	A
4297569	Flies	Oct 1981	A
4301412	Hill et al.	Nov 1981	A
4303887	Hill et al.	Dec 1981	A
4323536	Columbus	Apr 1982	A
4329642	Luthi et al.	May 1982	A
4366033	Richter et al.	Dec 1982	A
4407290	Wilber	Oct 1983	A
4407959	Tsuji et al.	Oct 1983	A
4413407	Columbus	Nov 1983	A
4413628	Tamulis	Nov 1983	A
4420564	Tsuji et al.	Dec 1983	A
4431004	Bessman et al.	Feb 1984	A
4436094	Cerami	Mar 1984	A
4440175	Wilkins	Apr 1984	A
4476149	Poppe et al.	Oct 1984	A
4477314	Richter et al.	Oct 1984	A
4477575	Vogel et al.	Oct 1984	A
4499423	Matthiessen	Feb 1985	A
4510383	Ruppender	Apr 1985	A
4517291	Seago	May 1985	A
4545382	Higgins et al.	Oct 1985	A
4547735	Kiesewetter et al.	Oct 1985	A
4552458	Lowne	Nov 1985	A
4571292	Liu et al.	Feb 1986	A
4578716	Van Rijckevorsel et al.	Mar 1986	A
4592893	Poppe et al.	Jun 1986	A
4628193	Blum	Dec 1986	A
4642295	Baker	Feb 1987	A
4648665	Davis et al.	Mar 1987	A
4652830	Brown	Mar 1987	A
4654197	Lilja et al.	Mar 1987	A
4671288	Gough	Jun 1987	A
4676653	Strohmeier et al.	Jun 1987	A
4679562	Luksha	Jul 1987	A
4682602	Prohaska	Jul 1987	A
4686479	Young et al.	Aug 1987	A
4703017	Campbell et al.	Oct 1987	A
4703756	Gough et al.	Nov 1987	A
4711245	Higgins et al.	Dec 1987	A
4713165	Conover et al.	Dec 1987	A
4713347	Mitchell et al.	Dec 1987	A
4714874	Morris et al.	Dec 1987	A
4731726	Allen, III	Mar 1988	A
4734184	Burleigh et al.	Mar 1988	A
4750496	Reinhart et al.	Jun 1988	A
4759828	Young et al.	Jul 1988	A
4789804	Karube et al.	Dec 1988	A
4795542	Ross et al.	Jan 1989	A
4797256	Watlington, IV	Jan 1989	A
4801424	Schweiger	Jan 1989	A
4805624	Yao et al.	Feb 1989	A
4806311	Greenquist	Feb 1989	A
4806312	Greenquist	Feb 1989	A
4810203	Komatsu	Mar 1989	A
4812210	Bonivert et al.	Mar 1989	A
4816224	Vogel et al.	Mar 1989	A
4820399	Senda et al.	Apr 1989	A
4820636	Hill et al.	Apr 1989	A
4832814	Root	May 1989	A
4834234	Sacherer et al.	May 1989	A
4849330	Humphries et al.	Jul 1989	A
4865873	Cole, Jr. et al.	Sep 1989	A
4877580	Aronowitz et al.	Oct 1989	A
4897162	Lewandowski et al.	Jan 1990	A
4897173	Nankai et al.	Jan 1990	A
4919770	Preidel et al.	Apr 1990	A
4927516	Yamaguchi et al.	May 1990	A
4929426	Bodai et al.	May 1990	A
4935105	Churchouse	Jun 1990	A
4935106	Liston et al.	Jun 1990	A
4935346	Phillips et al.	Jun 1990	A
4938860	Wogoman	Jul 1990	A
4940945	Littlejohn et al.	Jul 1990	A
4954087	Lauks et al.	Sep 1990	A
4956275	Zuk et al.	Sep 1990	A
4960546	Tharp	Oct 1990	A
4963814	Parks	Oct 1990	A
4965051	Shukunobe et al.	Oct 1990	A
4970145	Bennetto et al.	Nov 1990	A
4975647	Downer et al.	Dec 1990	A
4976724	Nieto et al.	Dec 1990	A
4999582	Parks et al.	Mar 1991	A
4999632	Parks	Mar 1991	A
5018164	Brewer et al.	May 1991	A
5019974	Beckers	May 1991	A
5035862	Dietze et al.	Jul 1991	A
5039618	Stone	Aug 1991	A
5049487	Phillips et al.	Sep 1991	A
5053199	Keiser et al.	Oct 1991	A
5059394	Phillips et al.	Oct 1991	A
5062458	Rohleder et al.	Nov 1991	A
5066372	Weetall	Nov 1991	A
5075077	Durley, III et al.	Dec 1991	A
5096669	Lauks et al.	Mar 1992	A
5108564	Szuminsky et al.	Apr 1992	A
5112455	Cozzette et al.	May 1992	A
5112758	Fellman et al.	May 1992	A
5118183	Cargill et al.	Jun 1992	A
5120420	Nankai et al.	Jun 1992	A
5122244	Hoenes et al.	Jun 1992	A
5126952	Kildal-Brandt et al.	Jun 1992	A
5128015	Szuminsky et al.	Jul 1992	A
5141850	Cole et al.	Aug 1992	A
5141868	Shanks et al.	Aug 1992	A
5143694	Schafer et al.	Sep 1992	A
5179005	Phillips et al.	Jan 1993	A
5179288	Miffitt et al.	Jan 1993	A
5182707	Cooper et al.	Jan 1993	A
5185256	Nankai	Feb 1993	A
5187100	Matzinger et al.	Feb 1993	A
5192415	Yoshioka et al.	Mar 1993	A
5220920	Gharib	Jun 1993	A
5232516	Hed	Aug 1993	A
5232667	Hieb et al.	Aug 1993	A
5232668	Grant et al.	Aug 1993	A
5234813	McGeehan et al.	Aug 1993	A
5243516	White	Sep 1993	A
5246858	Arbuckle et al.	Sep 1993	A
5250439	Musho et al.	Oct 1993	A
5261411	Hughes	Nov 1993	A
5264103	Yoshioka et al.	Nov 1993	A
5266179	Nankai et al.	Nov 1993	A
5269891	Colin	Dec 1993	A
5272060	Hamamoto et al.	Dec 1993	A
5279294	Anderson et al.	Jan 1994	A
5281395	Markart et al.	Jan 1994	A
5284770	Adrian et al.	Feb 1994	A
5286362	Hoenes et al.	Feb 1994	A
5288636	Pollmann et al.	Feb 1994	A
5296192	Carroll et al.	Mar 1994	A
5304468	Phillips et al.	Apr 1994	A
5306623	Kiser et al.	Apr 1994	A
5311426	Donohue et al.	May 1994	A
5312762	Guiseppi-Elie	May 1994	A
5324335	Benham et al.	Jun 1994	A
5332479	Uenoyama et al.	Jul 1994	A
5344754	Zweig	Sep 1994	A
5352351	White et al.	Oct 1994	A
5353351	Bartoli et al.	Oct 1994	A
5366609	White et al.	Nov 1994	A
5371687	Holmes, II et al.	Dec 1994	A
5376254	Fisher	Dec 1994	A
5379214	Arbuckle et al.	Jan 1995	A
5384028	Ito	Jan 1995	A
5385846	Kuhn et al.	Jan 1995	A
5389215	Horiuchi et al.	Feb 1995	A
5395504	Saurer et al.	Mar 1995	A
5405511	White et al.	Apr 1995	A
5411647	Johnson et al.	May 1995	A
5413690	Kost et al.	May 1995	A
5413764	Haar	May 1995	A
5418142	Kiser et al.	May 1995	A
5421189	Dussault	Jun 1995	A
5424035	Hones et al.	Jun 1995	A
5426032	Phillips et al.	Jun 1995	A
5437772	De Castro et al.	Aug 1995	A
5437999	Diebold et al.	Aug 1995	A
5438271	White et al.	Aug 1995	A
5439826	Kontorovich	Aug 1995	A
5445967	Deuter	Aug 1995	A
5447837	Urnovitz	Sep 1995	A
5453360	Yu	Sep 1995	A
5469846	Khan	Nov 1995	A
5470533	Shindo et al.	Nov 1995	A
5477326	Dosmann	Dec 1995	A
5489414	Schreiber et al.	Feb 1996	A
5494638	Gullick	Feb 1996	A
5500350	Baker et al.	Mar 1996	A
5504011	Gavin et al.	Apr 1996	A
5508171	Walling et al.	Apr 1996	A
5508200	Tiffany et al.	Apr 1996	A
5508203	Fuller et al.	Apr 1996	A
5509410	Hill et al.	Apr 1996	A
5515170	Matzinger et al.	May 1996	A
5515847	Braig et al.	May 1996	A
5526111	Collins et al.	Jun 1996	A
5526120	Jina et al.	Jun 1996	A
5526808	Kaminsky	Jun 1996	A
5527473	Ackerman	Jun 1996	A
5532128	Eggers et al.	Jul 1996	A
5547702	Gleisner	Aug 1996	A
5552116	Yokota et al.	Sep 1996	A
5554531	Zweig	Sep 1996	A
5556789	Goerlach-Graw et al.	Sep 1996	A
5563031	Yu	Oct 1996	A
5563042	Phillips et al.	Oct 1996	A
5563863	Hiramatsu	Oct 1996	A
5569591	Kell et al.	Oct 1996	A
5569608	Sommer	Oct 1996	A
5572159	McFarland	Nov 1996	A
5575895	Ikeda et al.	Nov 1996	A
5575930	Tetje-Girault et al.	Nov 1996	A
5576073	Kickelhain	Nov 1996	A
5580794	Allen	Dec 1996	A
5582697	Ikeda et al.	Dec 1996	A
5583432	Barnes	Dec 1996	A
5593390	Castellano et al.	Jan 1997	A
5593739	Kickelhain	Jan 1997	A
5594906	Holmes, II et al.	Jan 1997	A
5597532	Connolly	Jan 1997	A
5601694	Maley	Feb 1997	A
5604110	Baker et al.	Feb 1997	A
5605662	Heller et al.	Feb 1997	A
5605837	Karimi et al.	Feb 1997	A
5611900	Worden et al.	Mar 1997	A
5620579	Genshaw et al.	Apr 1997	A
5620863	Tomasco et al.	Apr 1997	A
5627075	Bateson	May 1997	A
5628890	Carter et al.	May 1997	A
5630986	Charlton et al.	May 1997	A
5635362	Levine et al.	Jun 1997	A
5635364	Clark et al.	Jun 1997	A
5639671	Bogart et al.	Jun 1997	A
5642734	Ruben et al.	Jul 1997	A
5645798	Schreiber et al.	Jul 1997	A
5650061	Kuhr et al.	Jul 1997	A
5650062	Ikeda et al.	Jul 1997	A
5653863	Genshaw et al.	Aug 1997	A
5654178	Fitzpatrick et al.	Aug 1997	A
5656502	MacKay et al.	Aug 1997	A
5658443	Yamamoto et al.	Aug 1997	A
5658802	Hayes et al.	Aug 1997	A
5665215	Bussmann et al.	Sep 1997	A
5670031	Hintsche et al.	Sep 1997	A
5677546	Yu	Oct 1997	A
5682884	Hill et al.	Nov 1997	A
5686659	Neel et al.	Nov 1997	A
5691486	Behringer et al.	Nov 1997	A
5691633	Liu et al.	Nov 1997	A
5695623	Michel et al.	Dec 1997	A
5698083	Glass	Dec 1997	A
5700695	Yassinzadeh et al.	Dec 1997	A
5708247	McAleer et al.	Jan 1998	A
5710622	Neel et al.	Jan 1998	A
5719667	Miers	Feb 1998	A
5720862	Hamamoto et al.	Feb 1998	A
5723284	Ye	Mar 1998	A
5727548	Hill et al.	Mar 1998	A
5728074	Castellano et al.	Mar 1998	A
5745308	Spangenberg	Apr 1998	A
5748002	Scott et al.	May 1998	A
5753101	Ludwig	May 1998	A
5757666	Schreiber et al.	May 1998	A
5759794	Levine et al.	Jun 1998	A
5762770	Pritchard et al.	Jun 1998	A
5766789	James et al.	Jun 1998	A
5776710	Levine et al.	Jul 1998	A
5780304	Matzinger et al.	Jul 1998	A
5786584	Button et al.	Jul 1998	A
5788833	Lewis et al.	Aug 1998	A
5789255	Yu	Aug 1998	A
5792668	Deamer et al.	Aug 1998	A
5798031	Charlton et al.	Aug 1998	A
5801057	Smart et al.	Sep 1998	A
5820551	Hill et al.	Oct 1998	A
5820622	Gross et al.	Oct 1998	A
5832921	Lennert et al.	Nov 1998	A
5834217	Levine et al.	Nov 1998	A
5837546	Allen et al.	Nov 1998	A
5843691	Douglas et al.	Dec 1998	A
5843692	Phillips et al.	Dec 1998	A
5846744	Athey et al.	Dec 1998	A
5849174	Sanghera et al.	Dec 1998	A
5856195	Charlton et al.	Jan 1999	A
5863400	Drummond et al.	Jan 1999	A
5869972	Birch et al.	Feb 1999	A
5873990	Wojciechowski et al.	Feb 1999	A
5883378	Irish et al.	Mar 1999	A
5885839	Lingane et al.	Mar 1999	A
5890489	Elden	Apr 1999	A
5897522	Nitzan	Apr 1999	A
5904898	Markart	May 1999	A
5911872	Lewis et al.	Jun 1999	A
5916156	Hildenbrand et al.	Jun 1999	A
5921925	Cartmell et al.	Jul 1999	A
5922530	Yu	Jul 1999	A
5922591	Anderson et al.	Jul 1999	A
5925021	Castellano et al.	Jul 1999	A
5925293	Howk	Jul 1999	A
5945341	Howard, III	Aug 1999	A
5948289	Noda et al.	Sep 1999	A
5951836	McAleer et al.	Sep 1999	A
5958215	Kuhr et al.	Sep 1999	A
5965380	Heller et al.	Oct 1999	A
5968760	Phillips et al.	Oct 1999	A
5971923	Finger	Oct 1999	A
5989917	McAleer et al.	Nov 1999	A
5997817	Crismore et al.	Dec 1999	A
6001239	Douglas et al.	Dec 1999	A
6004441	Fujiwara et al.	Dec 1999	A
6004442	Choulga et al.	Dec 1999	A
6013170	Meade	Jan 2000	A
6036919	Thym et al.	Mar 2000	A
6042714	Lin et al.	Mar 2000	A
6044285	Chaiken et al.	Mar 2000	A
6045567	Taylor et al.	Apr 2000	A
6061128	Zweig et al.	May 2000	A
6071391	Gotoh et al.	Jun 2000	A
6087182	Jeng et al.	Jul 2000	A
6091975	Daddona et al.	Jul 2000	A
6096186	Warburton	Aug 2000	A
6102872	Doneen et al.	Aug 2000	A
6103033	Say et al.	Aug 2000	A
6120676	Heller et al.	Sep 2000	A
6121009	Heller et al.	Sep 2000	A
6121050	Han	Sep 2000	A
6126609	Keith et al.	Oct 2000	A
6128519	Say	Oct 2000	A
6129823	Hughes et al.	Oct 2000	A
6134461	Say et al.	Oct 2000	A
6136549	Feistel	Oct 2000	A
6136610	Polito et al.	Oct 2000	A
6143164	Heller et al.	Nov 2000	A
6143247	Sheppard, Jr. et al.	Nov 2000	A
6144869	Berner et al.	Nov 2000	A
6150124	Riedel	Nov 2000	A
6153069	Pottgen et al.	Nov 2000	A
RE36991	Yamamoto et al.	Dec 2000	E
6156051	Schraga	Dec 2000	A
6156173	Gotoh et al.	Dec 2000	A
6159745	Roberts et al.	Dec 2000	A
6162611	Heller et al.	Dec 2000	A
6162639	Douglas	Dec 2000	A
6168563	Brown	Jan 2001	B1
6168957	Matzinger et al.	Jan 2001	B1
6170318	Lewis	Jan 2001	B1
6174420	Hodges et al.	Jan 2001	B1
6175752	Say et al.	Jan 2001	B1
6176988	Kessler	Jan 2001	B1
6179979	Hodges et al.	Jan 2001	B1
6180062	Naka et al.	Jan 2001	B1
6180416	Kurnik et al.	Jan 2001	B1
6193873	Ohara et al.	Feb 2001	B1
6197040	LeVaughn et al.	Mar 2001	B1
6200773	Ouyang et al.	Mar 2001	B1
6201607	Roth et al.	Mar 2001	B1
6203952	O'Brien et al.	Mar 2001	B1
6206282	Hayes, Sr. et al.	Mar 2001	B1
6206292	Robertz et al.	Mar 2001	B1
6218571	Zheng et al.	Apr 2001	B1
6225078	Ikeda et al.	May 2001	B1
6226081	Fantone et al.	May 2001	B1
6232062	Kayyem et al.	May 2001	B1
6241862	McAleer et al.	Jun 2001	B1
6246330	Nielsen	Jun 2001	B1
6246893	Gobeli	Jun 2001	B1
6246966	Perry	Jun 2001	B1
6251260	Heller et al.	Jun 2001	B1
6258229	Winarta et al.	Jul 2001	B1
6258254	Miyamoto et al.	Jul 2001	B1
6259937	Schulman et al.	Jul 2001	B1
6261519	Harding et al.	Jul 2001	B1
6262749	Finger et al.	Jul 2001	B1
6268162	Phillips et al.	Jul 2001	B1
6270637	Crismore et al.	Aug 2001	B1
6271044	Ballerstadt et al.	Aug 2001	B1
6272364	Kurnik	Aug 2001	B1
6277641	Yager	Aug 2001	B1
6281006	Heller et al.	Aug 2001	B1
6284125	Hodges et al.	Sep 2001	B1
6284550	Carroll et al.	Sep 2001	B1
6287451	Winarta et al.	Sep 2001	B1
6287595	Loewy et al.	Sep 2001	B1
6287875	Geisberg	Sep 2001	B1
6294281	Heller	Sep 2001	B1
6295506	Heinonen et al.	Sep 2001	B1
6299757	Feldman et al.	Oct 2001	B1
6300123	Vadgama et al.	Oct 2001	B1
6300141	Segal et al.	Oct 2001	B1
6300142	Andrewes et al.	Oct 2001	B1
6300961	Finger et al.	Oct 2001	B1
6309526	Fujiwara et al.	Oct 2001	B1
6315951	Markart	Nov 2001	B1
6316264	Corey et al.	Nov 2001	B1
6325917	Maxwell et al.	Dec 2001	B1
6326160	Dunn et al.	Dec 2001	B1
6329161	Heller et al.	Dec 2001	B1
6330464	Colvin, Jr. et al.	Dec 2001	B1
6331438	Aylott et al.	Dec 2001	B1
6333019	Coppens	Dec 2001	B1
6335203	Patel et al.	Jan 2002	B1
6338790	Feldman et al.	Jan 2002	B1
6340428	Ikeda et al.	Jan 2002	B1
6342364	Watanabe et al.	Jan 2002	B1
6344490	DeGeorge et al.	Feb 2002	B1
6349230	Kawanaka	Feb 2002	B1
6358752	Durst et al.	Mar 2002	B1
6377894	Deweese et al.	Apr 2002	B1
6377896	Sato et al.	Apr 2002	B1
6379513	Chambers et al.	Apr 2002	B1
6389891	D'Angelico et al.	May 2002	B1
6391558	Henkens et al.	May 2002	B1
6391645	Huang et al.	May 2002	B1
6394952	Anderson et al.	May 2002	B1
6395227	Kiser et al.	May 2002	B1
6399258	O'Brien et al.	Jun 2002	B2
6401532	Lubbers	Jun 2002	B2
6413213	Essenpreis et al.	Jul 2002	B1
6413395	Bhullar et al.	Jul 2002	B1
6413410	Hodges et al.	Jul 2002	B1
6420128	Ouyang et al.	Jul 2002	B1
6423218	Lindermeir et al.	Jul 2002	B1
6444115	Hodges et al.	Sep 2002	B1
6447657	Bhullar et al.	Sep 2002	B1
6454921	Hodges et al.	Sep 2002	B1
6458258	Taniike et al.	Oct 2002	B2
6461496	Feldman et al.	Oct 2002	B1
6475360	Hodges et al.	Nov 2002	B1
6475372	Ohara et al.	Nov 2002	B1
6484046	Say et al.	Nov 2002	B1
6485923	Yani et al.	Nov 2002	B1
6488827	Shartle	Dec 2002	B1
6489133	Phillips et al.	Dec 2002	B2
6491803	Shen et al.	Dec 2002	B1
6491870	Patel et al.	Dec 2002	B2
6501976	Sohrab	Dec 2002	B1
6503381	Gotoh et al.	Jan 2003	B1
6512986	Harmon	Jan 2003	B1
6514718	Heller et al.	Feb 2003	B2
6514769	Lee	Feb 2003	B2
6521110	Hodges et al.	Feb 2003	B1
6521182	Shartle et al.	Feb 2003	B1
6525330	Paolini et al.	Feb 2003	B2
6525549	Poellmann	Feb 2003	B1
6526298	Khalil et al.	Feb 2003	B1
6531040	Musho et al.	Mar 2003	B2
6531239	Heller	Mar 2003	B2
6531322	Jurik et al.	Mar 2003	B1
6538735	Duebendorfer et al.	Mar 2003	B1
6540890	Bhullar et al.	Apr 2003	B1
6540891	Stewart et al.	Apr 2003	B1
6541266	Modzelewski et al.	Apr 2003	B2
6544474	Douglas	Apr 2003	B2
6549796	Sohrab	Apr 2003	B2
6551494	Heller et al.	Apr 2003	B1
6555061	Leong et al.	Apr 2003	B1
6557427	Weigl et al.	May 2003	B2
6558528	Matzinger	May 2003	B1
6560471	Heller et al.	May 2003	B1
6561978	Conn et al.	May 2003	B1
6561989	Whitson	May 2003	B2
6562625	Modzelewski et al.	May 2003	B2
6565509	Say et al.	May 2003	B1
6565738	Henning et al.	May 2003	B1
6570390	Hirayama et al.	May 2003	B2
6571651	Hodges	Jun 2003	B1
6572822	Jurik et al.	Jun 2003	B2
6574425	Weiss et al.	Jun 2003	B1
6576101	Heller et al.	Jun 2003	B1
6576117	Iketaki et al.	Jun 2003	B1
6576416	Haviland et al.	Jun 2003	B2
6576461	Heller et al.	Jun 2003	B2
6579690	Bonnecaze et al.	Jun 2003	B1
6591125	Buse et al.	Jul 2003	B1
6592744	Hodges et al.	Jul 2003	B1
6592745	Feldman et al.	Jul 2003	B1
6594514	Berner et al.	Jul 2003	B2
6599406	Kawanaka et al.	Jul 2003	B1
6599407	Taniike et al.	Jul 2003	B2
6600997	Deweese et al.	Jul 2003	B2
6605200	Mao et al.	Aug 2003	B1
6605201	Mao et al.	Aug 2003	B1
6607658	Heller et al.	Aug 2003	B1
6616819	Liamos et al.	Sep 2003	B1
6618603	Varalli et al.	Sep 2003	B2
6618934	Feldman et al.	Sep 2003	B1
6623501	Heller et al.	Sep 2003	B2
6627057	Bhullar et al.	Sep 2003	B1
6632349	Hodges et al.	Oct 2003	B1
6635167	Batman et al.	Oct 2003	B1
6638415	Hodges et al.	Oct 2003	B1
6638716	Heller et al.	Oct 2003	B2
6645359	Bhullar et al.	Nov 2003	B1
6645368	Beaty et al.	Nov 2003	B1
6654625	Say et al.	Nov 2003	B1
6656702	Yugawa et al.	Dec 2003	B1
6660141	Minter et al.	Dec 2003	B1
6676995	Dick et al.	Jan 2004	B2
6689411	Dick et al.	Feb 2004	B2
6716620	Bashir et al.	Apr 2004	B2
6719887	Hasegawa et al.	Apr 2004	B2
6723371	Chih-Lui	Apr 2004	B2
6740518	Duong et al.	May 2004	B1
6743635	Neel et al.	Jun 2004	B2
6746582	Heller et al.	Jun 2004	B2
6749740	Liamos et al.	Jun 2004	B2
6764581	Forrow et al.	Jul 2004	B1
6776888	Yamamoto et al.	Aug 2004	B2
6777243	Fukuoka et al.	Aug 2004	B2
6787013	Chang et al.	Sep 2004	B2
6797039	Spencer	Sep 2004	B2
6800488	Khan et al.	Oct 2004	B2
6814844	Bhullar et al.	Nov 2004	B2
6818180	Douglas	Nov 2004	B2
6821483	Phillips et al.	Nov 2004	B2
6824670	Tokunaga et al.	Nov 2004	B2
6827829	Kawanaka et al.	Dec 2004	B2
6830669	Miyazaki et al.	Dec 2004	B2
6833110	Black	Dec 2004	B2
6841389	Novikov et al.	Jan 2005	B2
6856125	Kermani	Feb 2005	B2
6860978	Yamanishi et al.	Mar 2005	B2
6863800	Karinka	Mar 2005	B2
6881322	Tokunaga et al.	Apr 2005	B2
6881550	Phillips et al.	Apr 2005	B2
6881551	Heller	Apr 2005	B2
7018843	Heller	Mar 2006	B2
7022218	Taniike et al.	Apr 2006	B2
7041206	Gephart et al.	May 2006	B2
7050843	Shartle et al.	May 2006	B2
7390667	Burke et al.	Jun 2008	B2
7407811	Burke et al.	Aug 2008	B2
7429865	Dreibholz et al.	Sep 2008	B2
7488601	Burke et al.	Feb 2009	B2
8298828	Diebold et al.	Oct 2012	B2
20010006149	Taniike et al.	Jul 2001	A1
20010006150	Taniike et al.	Jul 2001	A1
20010017269	Heller et al.	Aug 2001	A1
20010019831	Phillips et al.	Sep 2001	A1
20010028032	Church et al.	Oct 2001	A1
20010034068	Spivey et al.	Oct 2001	A1
20010039057	Douglas et al.	Nov 2001	A1
20010041830	Varalli et al.	Nov 2001	A1
20010042683	Musho et al.	Nov 2001	A1
20010052470	Hodges et al.	Dec 2001	A1
20010053535	Bashir et al.	Dec 2001	A1
20010054319	Heller et al.	Dec 2001	A1
20010055784	Noda et al.	Dec 2001	A1
20020003087	Chih-hui	Jan 2002	A1
20020004196	Whitson	Jan 2002	A1
20020008038	Heller et al.	Jan 2002	A1
20020019707	Cohen et al.	Feb 2002	A1
20020023489	Reimelt et al.	Feb 2002	A1
20020025469	Heller	Feb 2002	A1
20020029058	LeVaughn et al.	Mar 2002	A1
20020033345	Meade	Mar 2002	A1
20020040850	Liu et al.	Apr 2002	A1
20020042090	Heller et al.	Apr 2002	A1
20020042558	Mendelson	Apr 2002	A1
20020043471	Ikeda et al.	Apr 2002	A1
20020044890	Black	Apr 2002	A1
20020053523	Liamos et al.	May 2002	A1
20020072784	Sheppard et al.	Jun 2002	A1
20020081588	De Lumley-woodyear et al.	Jun 2002	A1
20020082797	Deweese et al.	Jun 2002	A1
20020084184	Chambers et al.	Jul 2002	A1
20020084196	Liamos et al.	Jul 2002	A1
20020092612	Davies et al.	Jul 2002	A1
20020100685	Huang et al.	Aug 2002	A1
20020102739	Nomura et al.	Aug 2002	A1
20020112969	Hodges et al.	Aug 2002	A1
20020117404	Maxwell et al.	Aug 2002	A1
20020117639	Paolini et al.	Aug 2002	A1
20020121314	Tao et al.	Sep 2002	A1
20020125145	Ohara et al.	Sep 2002	A1
20020130042	Moerman et al.	Sep 2002	A1
20020130043	Hodges et al.	Sep 2002	A1
20020133064	Ueno et al.	Sep 2002	A1
20020137200	Takahashi et al.	Sep 2002	A1
20020137230	Nadaoka et al.	Sep 2002	A1
20020138275	Amano et al.	Sep 2002	A1
20020138356	Dutta et al.	Sep 2002	A1
20020139692	Tokunaga et al.	Oct 2002	A1
20020144895	Stern et al.	Oct 2002	A1
20020146835	Modzelewski et al.	Oct 2002	A1
20020148726	Yamamoto et al.	Oct 2002	A1
20020148739	Liamos et al.	Oct 2002	A2
20020150930	Nadaoka et al.	Oct 2002	A1
20020152793	Sato et al.	Oct 2002	A1
20020155030	Matsuda et al.	Oct 2002	A1
20020155615	Novikov et al.	Oct 2002	A1
20020157948	Liamos et al.	Oct 2002	A2
20020160517	Modzelewski et al.	Oct 2002	A1
20020164822	Takahashi et al.	Nov 2002	A1
20020168290	Yuzhakov et al.	Nov 2002	A1
20020168298	Huhn et al.	Nov 2002	A1
20020170823	Housefield et al.	Nov 2002	A1
20020175075	Deng et al.	Nov 2002	A1
20020175087	Hodges et al.	Nov 2002	A1
20020177135	Doung et al.	Nov 2002	A1
20020177788	Hodges et al.	Nov 2002	A1
20020179440	Tokunaga et al.	Dec 2002	A1
20020179441	Yamanishi et al.	Dec 2002	A1
20020179442	Miyazaki et al.	Dec 2002	A1
20020185385	Charlton	Dec 2002	A1
20020189941	Katsuki	Dec 2002	A1
20020192115	Bhullar et al.	Dec 2002	A1
20030000834	Yoshioka et al.	Jan 2003	A1
20030001295	Okajima et al.	Jan 2003	A1
20030004403	Drinan et al.	Jan 2003	A1
20030024811	Davies et al.	Feb 2003	A1
20030032875	Taniike et al.	Feb 2003	A1
20030036202	Teodorcyzk et al.	Feb 2003	A1
20030042137	Mao et al.	Mar 2003	A1
20030042150	Ryu et al.	Mar 2003	A1
20030046811	Chang et al.	Mar 2003	A1
20030054427	Phillips et al.	Mar 2003	A1
20030057132	Wittenbrink et al.	Mar 2003	A1
20030062263	Stanford et al.	Apr 2003	A1
20030064525	Liess	Apr 2003	A1
20030073151	Phillips et al.	Apr 2003	A1
20030073152	Phillips et al.	Apr 2003	A1
20030073153	Phillips et al.	Apr 2003	A1
20030079987	Hodges et al.	May 2003	A1
20030080001	Hodges et al.	May 2003	A1
20030080446	Cheng	May 2003	A1
20030087970	Wittenbrink et al.	May 2003	A1
20030088166	Say et al.	May 2003	A1
20030094383	Kermani	May 2003	A1
20030094384	Vreeke et al.	May 2003	A1
20030097981	Dick et al.	May 2003	A1
20030098233	Kermani et al.	May 2003	A1
20030098234	Hasegawa et al.	May 2003	A1
20030099773	Dick et al.	May 2003	A1
20030100030	Nadaoka et al.	May 2003	A1
20030100040	Bonnecaze et al.	May 2003	A1
20030100821	Heller et al.	May 2003	A1
20030102213	Gotoh et al.	Jun 2003	A1
20030106809	Kermani et al.	Jun 2003	A1
20030108976	Braig et al.	Jun 2003	A1
20030109798	Kermani	Jun 2003	A1
20030113907	Roberts et al.	Jun 2003	A1
20030132110	Hasegawa et al.	Jul 2003	A1
20030134347	Heller et al.	Jul 2003	A1
20030143113	Yuzhakov et al.	Jul 2003	A2
20030143116	Zheng et al.	Jul 2003	A1
20030143556	Blackburn et al.	Jul 2003	A1
20030146110	Karinka et al.	Aug 2003	A1
20030146436	Parker et al.	Aug 2003	A1
20030150724	Kawanaka et al.	Aug 2003	A1
20030152823	Heller	Aug 2003	A1
20030155237	Surridge et al.	Aug 2003	A1
20030155538	Siepmann	Aug 2003	A1
20030159944	Pottgen et al.	Aug 2003	A1
20030159945	Miyazaki et al.	Aug 2003	A1
20030164293	Hodges et al.	Sep 2003	A1
20030167862	Hodges	Sep 2003	A1
20030168338	Gao et al.	Sep 2003	A1
20030175841	Watanabe et al.	Sep 2003	A1
20030175946	Tokunaga et al.	Sep 2003	A1
20030176183	Drucker et al.	Sep 2003	A1
20030178322	Iyengar et al.	Sep 2003	A1
20030179914	Tokunaga	Sep 2003	A1
20030180183	Fukuoka et al.	Sep 2003	A1
20030185705	Otake	Oct 2003	A1
20030187338	Say et al.	Oct 2003	A1
20030188427	Say et al.	Oct 2003	A1
20030190069	Nikitin et al.	Oct 2003	A1
20030199744	Buse et al.	Oct 2003	A1
20030199893	Boecker et al.	Oct 2003	A1
20030201194	Heller et al.	Oct 2003	A1
20030203498	Neel et al.	Oct 2003	A1
20030203503	Fukuoka et al.	Oct 2003	A1
20030217918	Davies et al.	Nov 2003	A1
20040005716	Beaty et al.	Jan 2004	A9
20040005721	Tanike et al.	Jan 2004	A1
20040016642	Miyazaki et al.	Jan 2004	A1
20040020777	Miyamoto et al.	Feb 2004	A1
20040067166	Karinka et al.	Apr 2004	A1
20040094432	Neel et al.	May 2004	A1
20040094433	Neel et al.	May 2004	A1
20040096928	Hasegawa et al.	May 2004	A1
20040099540	Neel et al.	May 2004	A1
20040104131	Neel et al.	Jun 2004	A1
20040106941	Roe et al.	Jun 2004	A1
20040118681	Hellinga et al.	Jun 2004	A1
20040123738	Spencer	Jul 2004	A1
20040127818	Roe et al.	Jul 2004	A1
20040127819	Roe et al.	Jul 2004	A1
20040157337	Burke et al.	Aug 2004	A1
20040182703	Bell et al.	Sep 2004	A1
20040206623	D'Ambra et al.	Oct 2004	A1
20040206625	Bhullar et al.	Oct 2004	A1
20040235178	Tokunaga et al.	Nov 2004	A1
20040256248	Burke et al.	Dec 2004	A1
20040259180	Burke et al.	Dec 2004	A1
20040260511	Burke et al.	Dec 2004	A1
20050013731	Burke et al.	Jan 2005	A1
20050016844	Burke et al.	Jan 2005	A1
20050019212	Bhullar et al.	Jan 2005	A1
20070264721	Buck	Nov 2007	A1
20080314882	Bhullar et al.	Dec 2008	A1

Foreign Referenced Citations (379)

Number	Date	Country
737 787	Aug 2001	AU
3245318	Jun 1984	DE
36 43 263	Jul 1988	DE
40 11 428	Nov 1990	DE
4011 428	Nov 1992	DE
298 14 997	Aug 1993	DE
199 36 693	Feb 2001	DE
0 010 456	Apr 1980	EP
0 034 049	Aug 1981	EP
0 057 110	Aug 1982	EP
0 057 110	Aug 1982	EP
0 073 056	Mar 1983	EP
0 084 874	Aug 1983	EP
0 101 880	Mar 1984	EP
0 127 958	Dec 1984	EP
0 034 049	Jan 1985	EP
0 132 790	Feb 1985	EP
0 164 180	Dec 1985	EP
0 164 180	Dec 1985	EP
0 170 375	Feb 1986	EP
0 171 148	Feb 1986	EP
0 171 148	Feb 1986	EP
0 171 239	Feb 1986	EP
0 186 286	Jul 1986	EP
0 186 286	Jul 1986	EP
0 207 370	Jan 1987	EP
0 230 472	Aug 1987	EP
0 241 309	Oct 1987	EP
0 255 291	Feb 1988	EP
0 267 724	May 1988	EP
0 287 883	Oct 1988	EP
0 287 883	Oct 1988	EP
0 359 831	Mar 1990	EP
0 359 831	Mar 1990	EP
0 383 322	Aug 1990	EP
0 206 218	Jun 1991	EP
0 471 986	Feb 1992	EP
0 471 986	Feb 1992	EP
0 471 986	Apr 1992	EP
0 537 761	Apr 1993	EP
0 546 536	Jun 1993	EP
0 546 536	Jun 1993	EP
0 244 326	Aug 1993	EP
0 255 291	Aug 1993	EP
0 537 761	Feb 1994	EP
0 417 796	Nov 1994	EP
0 213 343	Feb 1995	EP
0 636 880	Feb 1995	EP
0 640 832	Mar 1995	EP
0 651 250	May 1995	EP
0 471 986	Oct 1995	EP
0 732 406	Sep 1996	EP
0 732 590	Sep 1996	EP
0 736 607	Oct 1996	EP
0 740 786	Nov 1996	EP
0 537 761	Aug 1997	EP
0 837 320	Apr 1998	EP
0 840 122	May 1998	EP
0 851 224	Jul 1998	EP
0 851 224	Jul 1998	EP
0 859 230	Aug 1998	EP
0 873 514	Oct 1998	EP
0 876 506	Nov 1998	EP
0 878 713	Nov 1998	EP
10 307119	Nov 1998	EP
0 882 226	Dec 1998	EP
0 887 421	Dec 1998	EP
10 332626	Dec 1998	EP
0 894 509	Feb 1999	EP
0 470 649	Jun 1999	EP
0 942 278	Sep 1999	EP
0 958 495	Nov 1999	EP
956126	Nov 1999	EP
0 964 059	Dec 1999	EP
0 964 059	Dec 1999	EP
0 967 480	Dec 1999	EP
11 337514	Dec 1999	EP
0 987 544	Mar 2000	EP
0 987 544	Mar 2000	EP
1 009 850	Jun 2000	EP
1 024 358	Aug 2000	EP
1 035 216	Sep 2000	EP
1 067 384	Jan 2001	EP
1 074 832	Feb 2001	EP
1 081 490	Mar 2001	EP
1 102 991	May 2001	EP
1 119 637	Aug 2001	EP
1 129 211	Sep 2001	EP
1 130 390	Sep 2001	EP
0 741 186	Oct 2001	EP
1 143 245	Oct 2001	EP
1 147 739	Oct 2001	EP
1 152 239	Nov 2001	EP
1 156 324	Nov 2001	EP
1 156 324	Nov 2001	EP
1 225 448	Jul 2002	EP
1 225 448	Jul 2002	EP
1 235 069	Aug 2002	EP
1 236 995	Sep 2002	EP
1 253 204	Oct 2002	EP
0 958 495	Nov 2002	EP
1 256 798	Nov 2002	EP
1 256 798	Nov 2002	EP
1 260 589	Nov 2002	EP
102 22 428	Dec 2002	EP
0 800 086	Jan 2003	EP
1 275 732	Jan 2003	EP
1 275 732	Jan 2003	EP
1 281 955	Feb 2003	EP
1 281 955	Feb 2003	EP
1 288 653	Mar 2003	EP
1 288 654	Mar 2003	EP
1 308 720	May 2003	EP
1 312 919	May 2003	EP
1 467 496	May 2003	EP
1 316 367	Jun 2003	EP
1 316 367	Jun 2003	EP
1 318 396	Jun 2003	EP
0 876 506	Jul 2003	EP
1 324 025	Jul 2003	EP
1 324 038	Jul 2003	EP
1 327 881	Jul 2003	EP
1 327 881	Jul 2003	EP
1 352 611	Oct 2003	EP
1 352 969	Oct 2003	EP
1 352 969	Oct 2003	EP
1 369 684	Dec 2003	EP
1 369 684	Dec 2003	EP
1 369 687	Dec 2003	EP
1 369 687	Dec 2003	EP
1 391 716	Feb 2004	EP
1 119 637	Mar 2004	EP
1 394 535	Mar 2004	EP
1 394 535	Mar 2004	EP
1394545	Mar 2004	EP
1 413 879	Apr 2004	EP
1 431 758	Jun 2004	EP
1 431 758	Jun 2004	EP
1496354	Jan 2005	EP
281224	Oct 1926	GB
787123	Dec 1957	GB
2 295 676	Jun 1996	GB
2 365 123	Feb 2002	GB
2365123	Feb 2002	GB
91-59644	Jun 1977	JP
63-111453	May 1988	JP
63-128252	May 1988	JP
63128252	May 1988	JP
01-291153	Nov 1989	JP
1291153	Nov 1989	JP
03-099254	Apr 1991	JP
04-121652	Apr 1992	JP
05-312761	Nov 1993	JP
93-312761	Nov 1993	JP
08-262026	Oct 1996	JP
09-043242	Feb 1997	JP
09-189675	Jul 1997	JP
0609079	Jul 1998	JP
0592176	Dec 1998	JP
2000 019147	Jan 2000	JP
2001153839	Jun 2001	JP
2003015627	Oct 2002	JP
2002014687	Jan 2003	JP
2002511851	Mar 2003	JP
2180514	Mar 2002	RU
WO 8101794	Jul 1981	WO
WO 8300926	Mar 1983	WO
WO 8607632	Dec 1986	WO
WO 8908713	Sep 1989	WO
WO 8909397	Oct 1989	WO
WO 9005293	May 1990	WO
WO 9201928	Feb 1992	WO
WO 9207655	May 1992	WO
WO 9215859	Sep 1992	WO
WO 9215861	Sep 1992	WO
WO 9215950	Sep 1992	WO
WO 9222669	Dec 1992	WO
WO 9309433	May 1993	WO
WO 9412950	Jun 1994	WO
WO 9416095	Jul 1994	WO
WO 9416807	Aug 1994	WO
WO 9416807	Aug 1994	WO
WO 9423295	Oct 1994	WO
WO 9428414	Dec 1994	WO
WO 9429705	Dec 1994	WO
WO 9429706	Dec 1994	WO
WO 9503542	Feb 1995	WO
WO 9506919	Mar 1995	WO
WO 9507050	Mar 1995	WO
WO 9522597	Aug 1995	WO
WO 9504398	Feb 1996	WO
WO 9607908	Mar 1996	WO
WO 9613707	May 1996	WO
WO 9615454	May 1996	WO
WO 9626003	Aug 1996	WO
WO 9626003	Aug 1996	WO
WO 9633403	Oct 1996	WO
WO 9700441	Jan 1997	WO
WO 9702487	Jan 1997	WO
WO 9730344	Mar 1997	WO
WO 9716726	May 1997	WO
WO 9718465	May 1997	WO
WO 9729366	Aug 1997	WO
WO 9729847	Aug 1997	WO
WO 9730344	Aug 1997	WO
WO 9734140	Sep 1997	WO
WO 9739341	Oct 1997	WO
WO 9739343	Oct 1997	WO
WO 9742882	Nov 1997	WO
WO 9742888	Nov 1997	WO
WO 9745719	Dec 1997	WO
WO 9805424	Feb 1998	WO
WO 9819153	May 1998	WO
WO 9819159	May 1998	WO
WO 9829740	Jul 1998	WO
WO 9830904	Jul 1998	WO
WO 9835225	Aug 1998	WO
WO 9837168	Aug 1998	WO
WO 9837168	Aug 1998	WO
WO 9855853	Dec 1998	WO
WO 9857159	Dec 1998	WO
WO 9905516	Feb 1999	WO
WO 9905966	Feb 1999	WO
WO 9909404	Feb 1999	WO
WO 9912008	Mar 1999	WO
WO 9912021	Mar 1999	WO
WO 9913099	Mar 1999	WO
WO 9913100	Mar 1999	WO
WO 9922236	May 1999	WO
WO 9923479	May 1999	WO
WO 9929230	Jun 1999	WO
WO 9930152	Jun 1999	WO
WO 9932881	Jul 1999	WO
WO 9939627	Aug 1999	WO
WO 9941596	Aug 1999	WO
WO 9945387	Sep 1999	WO
9951974	Oct 1999	WO
9957317	Nov 1999	WO
9958709	Nov 1999	WO
9959464	Nov 1999	WO
9960383	Nov 1999	WO
9964620	Dec 1999	WO
WO 0019146	Jan 2000	WO
WO 0009996	Feb 2000	WO
WO 0010007	Feb 2000	WO
WO 0016089	Mar 2000	WO
WO 0018294	Apr 2000	WO
WO 0020626	Apr 2000	WO
WO 0026638	May 2000	WO
WO 0028068	May 2000	WO
WO 0033063	Jun 2000	WO
WO 0033063	Jun 2000	WO
WO 0033063	Jun 2000	WO
WO 0033072	Jun 2000	WO
WO 0033074	Jun 2000	WO
WO 0042422	Jul 2000	WO
WO 0042422	Jul 2000	WO
WO 0045160	Aug 2000	WO
WO 0054047	Sep 2000	WO
WO 0057177	Sep 2000	WO
WO 0060340	Oct 2000	WO
WO 0062047	Nov 2000	WO
WO 0066257	Nov 2000	WO
WO 0073778	Dec 2000	WO
WO 0073785	Dec 2000	WO
WO 0078917	Dec 2000	WO
WO 0078992	Dec 2000	WO
WO 0102093	Jan 2001	WO
WO 0128423	Feb 2001	WO
WO 0125775	Apr 2001	WO
WO 0125776	Apr 2001	WO
WO 0128423	Apr 2001	WO
WO 0130915	May 2001	WO
WO 0136430	May 2001	WO
WO 0136660	May 2001	WO
WO 0136953	May 2001	WO
2001-153839	Jun 2001	WO
WO 0136953	Jun 2001	WO
WO 0140787	Jun 2001	WO
WO 0140788	Jun 2001	WO
WO 0146457	Jun 2001	WO
WO 0140788	Jul 2001	WO
WO 0157238	Aug 2001	WO
WO 0157239	Aug 2001	WO
WO 0157510	Aug 2001	WO
WO 0164105	Sep 2001	WO
WO 0167099	Sep 2001	WO
WO 0171328	Sep 2001	WO
WO 0171329	Sep 2001	WO
WO 0172220	Oct 2001	WO
WO 0173109	Oct 2001	WO
WO 0173114	Oct 2001	WO
WO 0173124	Oct 2001	WO
WO 0173395	Oct 2001	WO
WO 0173419	Oct 2001	WO
WO 0173420	Oct 2001	WO
WO 0174242	Oct 2001	WO
WO 0175433	Oct 2001	WO
WO 0175438	Oct 2001	WO
WO 0184133	Nov 2001	WO
WO 0184142	Nov 2001	WO
WO 0188524	Nov 2001	WO
WO 0125775	Dec 2001	WO
WO 0192857	Dec 2001	WO
WO 0195806	Dec 2001	WO
WO 0196596	Dec 2001	WO
WO 0200112	Jan 2002	WO
WO 0208750	Jan 2002	WO
WO 0208753	Jan 2002	WO
WO 0266822	Jan 2002	WO
WO 0210728	Feb 2002	WO
WO 0213966	Feb 2002	WO
WO 0213970	Feb 2002	WO
WO 0214535	Feb 2002	WO
WO 0218053	Mar 2002	WO
WO 0222249	Mar 2002	WO
WO 0222855	Mar 2002	WO
WO 0232559	Apr 2002	WO
WO 0244705	Jun 2002	WO
WO 0248707	Jun 2002	WO
WO 0249507	Jun 2002	WO
WO 0250609	Jun 2002	WO
WO 02054055	Jul 2002	WO
WO 02054055	Jul 2002	WO
WO 02057767	Jul 2002	WO
WO 02057767	Jul 2002	WO
WO 02057768	Jul 2002	WO
WO 02057768	Jul 2002	WO
WO 02057781	Jul 2002	WO
WO 02058537	Aug 2002	WO
WO 02062212	Aug 2002	WO
WO 02067768	Sep 2002	WO
WO 02070734	Sep 2002	WO
WO 02071044	Sep 2002	WO
WO 02075833	Oct 2002	WO
WO 02078512	Oct 2002	WO
WO 02086483	Oct 2002	WO
WO 02093152	Nov 2002	WO
WO 02095355	Nov 2002	WO
WO 02097418	Dec 2002	WO
WO 02103343	Dec 2002	WO
WO 03005015	Jan 2003	WO
WO 03012422	Feb 2003	WO
WO 03014740	Feb 2003	WO
WO 03014741	Feb 2003	WO
WO 03015627	Feb 2003	WO
WO 03015629	Feb 2003	WO
WO 03019166	Mar 2003	WO
WO 03021706	Mar 2003	WO
WO 03025257	Mar 2003	WO
WO 03029804	Apr 2003	WO
WO 03032411	Apr 2003	WO
2002149192	May 2003	WO
WO 03039483	May 2003	WO
WO 03042679	May 2003	WO
WO 03042680	May 2003	WO
WO 03043945	May 2003	WO
WO 03044511	May 2003	WO
WO 03044513	May 2003	WO
WO 03048756	Jun 2003	WO
WO 03048756	Jun 2003	WO
WO 03056345	Jul 2003	WO
WO 03056345	Jul 2003	WO
WO 03060154	Jul 2003	WO
WO 03060154	Jul 2003	WO
WO 03067252	Aug 2003	WO
WO 03069304	Aug 2003	WO
WO 03083469	Oct 2003	WO
WO 03085372	Oct 2003	WO
WO 03091717	Nov 2003	WO
WO 2004005908	Jan 2004	WO
WO 2004020465	Jan 2004	WO
WO 2004034053	Apr 2004	WO
WO 2004034053	Apr 2004	WO
WO 2004113896	Dec 2004	WO
WO 2004113901	Dec 2004	WO
WO 2004113902	Dec 2004	WO
WO 2005003748	Jan 2005	WO
2006509187	Mar 2006	WO

Non-Patent Literature Citations (104)

Entry
US 6,517,703, 02/2003, Beaty et al. (withdrawn)
“Verarbeitung von Dispersionshaftlebstoffen”, 1022 Adhasion, 37 Dec. 1993, No. 12, Muchen, DE.
Aoki et al., “Time-Dependence of Diffusion-Controlled Currents of a Soluble Redox Couple at Interdigitated Microarray Electrodes,” J. Electroanal. Chem. 266 (1989) 11-20.
Aoki, Koichi; Theory of the Steady-State Current of a Redox Couple at Interdigitated Array Electrodes of Which Pairs are Insulated Electrically by Steps; J. Electroanal. Chem.; 1989; 35-41; 270; The Netherlands.
Bartlett, P.N. And Whitaker, R.G., “Electrochemical Immobilisation of Enzymes: Part II. Glucose Oxidase Immobilised in Poly-N-Methylpyrrole,” J. Electroanal. Chem., 224 (1987) 37-48.
Bartlett, P.N., and Whitaker, R.G., “Electrochemical Immobilisation of Enzymes: Part I. Theory,” J.Electroanal. Chem., 224 (1987) 27-35.
Bedell (“Admittance and Impedance Loci,” Proc. Phys. Soc. London 14 327-336) 1895.
Bradley et al., “Kinetic Analysis of Enzyme Electrode Response,” Anal. Chem., vol. 56, pp. 664-667 (1984).
Brevnov, D.A. et al., Journal of Electronanalytical Chemistry 2000, 488, 133-139.
Brian A. Gregg et al., “Cross-Linked Redox Gels Containing Glucose Oxidase for Amperometric Biosensor Applications”, Analytical Chemistry, Feb. 1, 1990, pp. 258-263, vol. 62, No. 3.
Burke, et al., Improved-Accuracy Biosensor Strip for AccuChek(TM) Advantage(R), Presented Orally at ACS Boston Meeting (˜1993-1994).
Canadian Patent Application No. 2,529,579 Office Action mailed Nov. 26, 2009.
Cardosi, et al., “The Realization of Electron Transfer from Biological Molecules to Electrodes,” Biosensors Fundamentals and Applications, chapt. 15, (Turner et al. eds., Oxford University Press. 1987).
Cass et al., “Ferrocene-Mediated Enzyme Electrode for Amperometric Determination of Glucose,” Anal. Chem., vol. 56, pp. 667-671 (1984).
Cha, K. et al., Physiological measurement 1994, 15, 2, 129-137.
Chiba, K et al., “Electrochemical Preparation of a Ladder Polymer Containing Phenazine Rings,” J Electroanal Chemo., 219 (1987) 117-124.
Cosimino Malitesta et al., “Glucose Fast-Response Amperometric Sensor Based on Glucose Oxidase Immobilized in an Electropolymerized Poly (o-phenylenediamine) Film”, Analytical Chemistry, Dec. 15, 1990, pp. 2735-2740, vol. 62, No. 24.
David L. Williams et al., “Electrochemical-Enzymatic Analysis of Blood Glucose and Lactate”, Analytical Chemistry, Jan. 1970, pp. 118-121, vol. 42, No. 1.
de Vries, P. M. J. M. et al, Medical and Biological Engineering and Computing, 1993, 31, 445-448.
De Vries, P.M.J.M. et al, Medical and Biological Engineering and Computing, 1993,31, 445-448.
Doss, J.D. et al, Medical Physics 1986, 13, 876-881.
Engblom, S.O. et al., Journal of Electroanalytical Chemistry 2000, 480, 120-132.
European Search Report for 09005912.2-2204.
Fare, T.L. et al, Biosensors & Bioelectronics 1998, 13, 459-470.
Gebhardt, et al., “Electrocatalytic Glucose Sensor,” Siemens Forsch-u, Entwickl-Ber. Bd., vol. 12, pp.91-95 (1983).
Hintsche, R. et al., “Chip Biosensors on Thin-Film Metal Electrodes,” Sensors and Actuators B. 4 (1991), pp. 284-291.
Ho et al., “Electrochemical Sensor for Measurement of Urea and Creatinine in Serum Based on AC Impedance Measurement of Enzyme-Catalyzed Polymer Transformation,” Analtyical Chemistry, vol. 71, No. 10, May 15, 1999.
http://216.239.41.104/search?q=cache:bEmigi1MhtUJ:www.coe.uncc.edu, “LER,” Ndubuisi George Orji, Jan. 2004, pp. 1-3.
http://216.239.41.104/search?q=cache:oNNpSzoOXvgJ:www.future-fab.com, “Introduction,” Future Fab International, Montgomery Research, Inc., Jan. 2004, pp. 1-10.
http://www.circuittree.com, Vaucher et al., “Laser Direct Imaging and Structuring: An Update,” posted on Aug. 2002, Nov. 2003, pp. 1-6
http://www.ifm.liu.se/App1phys/ftir/sams.html, “Self-Assembled Monolayers,” Jan. 2004, pp. 1-5.
http://www.tamsci.com/library/news-05-DECEMBER-2002.html, “Patterning Thin Film Circuits at the Speed of Llght,” Press Release, Nov. 2003, pp. 1-2
http://www.zurich.ibm.com/˜bmi/samtech.html, “Technological Application of Self-Assembled Monolayers,” Jan. 2004, pp. 1-2.
Ichikawa et al., Interface Dynamics of Capillary Flow in a Tube under Negligible Gravity Condition, Journal of Colloid and Interface Science 162, 350-355 (1994).
International Searcfh Report dates May 2, 2005 (PCT/EP2005/050999).
ISP Preservatives, GERMALL® PLUS, http://www.ispcorp.com/products/preservatives/content/products/germplus.html, printed Jan. 22, 2005, pp. 1-2.
ISP: Preservatives, GERMALL® II, http://www.ispcorp.com/products/preservatives/content/products/germii.html, printed Jan. 22, 2005, pp. 1-3.
Jaffrin, M.Y. et al., Medical and Biological Engineering and Computing 1999, 37, 433-439.
Japanese Patent Application 2006-517459 Office Action mailed Dec. 15, 2009.
Japanese Patent Application No. 517450/2006 Office Action mailed Dec. 15, 2009.
Jin et al., “Application of the Finite Analytic Numerical Method. Part 1. Diffusion Problems on Coplanar and Elevated Interdigitated Microarray Band Electrodes,” J. Electroanal. Chem. 441 (1996), pp. 29-36.
JP Patent Application No. 2006-517460 Office Action Translation in Part mailed Jul. 14, 2009.
Kasapbasioglu et al., “An Impedance Based Ultra-Thin Platinum Island Film Glucose Sensor,” Sensor and Actuators B. vol. 13-14, (1993), pp. 749-751.
Kim et al., Micro-channel filling flow considering surface tension effect, J. Micromech. Microeng. 12 (2002) 236-246.
Kim et al., Micro-channel Filling Flow Considering Surface Tension Effect, J. Micromech., Microeng. 12(2002) 236-246.
Koichi Aoki, “Quantitative analysis of reversible diffusion-controlled currents of redox soluble species at interdigitated array electrodes under steady-state conditions”, Journal of Electroanalytical Chemistry, pp. 269-282, issue/volume vol. 256, No. 2, Elsevier Sequoia S.A., Lausanne.
Koichi Aoki, “Theory of the steady-state current of a redox couple at interdigitated array electrodes of which pairs are insulated electrically by steps”, Journal of Electroanalytical Chemistry, Oct. 10, 1989, pp. 35-41, vol. 270.
Koichi, “Measurements of Current-Potential Curves, 6, Cottrell Equation and its Analogs. What Can We Know from Chronoamperometry?”, Denki Kagaku ovopi Kogyo Butsuri Kagaku, vol. 54, No. 6, (1986), pp. 471-475.
Lang, Werner; Zander, Rolf, “Physiological HEPES Buffer Proposed as a Calibrator for pH Measurement in Human Blood,” Clinical Chemistry and Laboratory Medicine, vol. 37, Issue 5, May 1999, pp. 563-571.
Lee, et al., “A New Glucose Sensor Using Microporous Enzyme Membrane,” Sensors and Actuators B, 3, (1991), 215-219.
Leonard M. Tender et al.,“Electrochemical Patterning of Self-Assembled Monolayers onto Microscopic Arrays of Gold Electrodes Fabricated by Laser Ablation”, Langmuir, pgs. 5515-5518 (1996), vol. 12, No. 23
Li, W. et al., Journal of Process Control 2002, 12, 429-443.
Lifescan Guide Entitled “Quick Start” for the Onetouch® Ultra™ Blood Glucose Monitoring System.
Lifescan Owner's Brooklet Entitled “The Comfort of Control”.
Lifescan Product Brochure for Onetouch® Ultra™ Blood Glucose Monitoring System.
Lifescan Product Brochure for Onetouch® Ultra™ Test Strip.
Luo, R. et al., Industrial & Engineering Chemistry Research 1998, 37, 1024-1032.
M. Beyer et al., “Development and application of a new enzyme sensor type based on the EIS-capacitance structure for bioprocess control”, Biosensors & Bioelectronics, 1994, pp. 17-21.
Maasrani, M. et al., Medical & biological engineering & computing 1997. 35, 3, 167-171.
Matsuhiko Nishizawa et al., “Penicillin Sensor Based on a Microarray Electrode Coated with pH-responsive Polypyrrole”, Analytical Chemistry, Nov. 1, 1992, pp. 2642-2644, vol. 64, No. 21.
Meier et al., “Sensor and Sensor Elements Manufacturing: Laser Direct Patterning (LDP) for Reel to Reel Processing to Generate High Throughput,” LPKF Laser & Electronics AG, pp. 1-6.
Mell et al., “A Model for the Amperometric Enzyme Electrode Obtained Through Digital Simulation and Applied to the Immobilized Glucose Oxidase System,” Analytical Chemistry, pp. 299-307, issue/vol. 47.
Mell et al., “Amperometric Response Enhancement of the Immobilized Glucose Oxidase Enzyme Electode,” Analytical Chemistry, pp. 1597-1601, issue/vol. 48.
Miao et al., “Aperometic Glucose Biosensor Based on Immobilization of Glucose Oxidase in Chitosan Matrix Cross-Linked with Glutaraldehyde,” Electroanalysis 2001, 13, No. 4, pp. 347-349.
Mohri, et al., “Characteristic Response of Electrochemical Nonlinearity to Taste Compounds with a Gold Electrode Modified with 4-Aminobenzenethiol,” Bull, Chem. Soc. Joh., vol. 66, pp. 1328-1332 (1993).
Muller et al., “Influence of Hematocrit and Platelet Count on Impedance and Reactivity of Whole Blood for Electrical Aggregometry,” Journal of Pharmacological and Toxicological Methods, vol. 34, pp. 17-22 (1995).
Myland et al., Membrane-Covered Oxygen Sensors: An Exact Treatment of the Switch-on Transient, Journal of the Electrochemical Society, vol. 131, pp. 1815-1823 (Aug. 1984).
N.A. Morris et al., “An Electrochemical Capillary Fill Device for the Analysis of Glucose Incorporating Glucose Oxidase and Ruthenium (III) Hexamine as Mediator”, Electroanalysis, 1992, pp. 1-9, vol. 4.
Niewiadomski, W. et al., Physics in Medicine and Biology 1990, 35, 1575-1583.
Nishihara et al., “Interdigitated Array Electrode Diffusion Measurements in Donor/Acceptor Solutions in Polyether Electrolyte Solvents,” Anal. Chem. 1991, 64, pp. 2955-2960.
Niwa et al., “Electrochemical Behavior of Reversible Redox Species at Interdigitated Array Electrodes with Different Geometries: Consideration of Redox Cycling and Collection Efficiency,” Anal. Chem. 62 (1990), pp. 447-452.
Olthof, C.G. et al., Medical and Biological Engineering and Computing 1994, 32, 495-500.
Osamu Niwa, “Fabrication and characteristics of vertically separated interdigitated array electrodes”, Journal of Electroanalytical Chemistry, Aug. 10, 1989, pp. 297-297, vol. 267.
Paeschke et al., “Properties of Interdigital Electrode Arrays with Different Geometries,” Analytical Chimica Acta 305 (1995), pp. 126-136.
Pages 320-322 of Microsystem Design by Stephen Senturia, Kluwer Academic Publishers (2002).
Patent Application Search Report Mailed on Sep. 5, 2008 for PCT/EP2008/003732.
Preidel et al., “Glucose Measurements by Electrocatalytic Sensor in the Extracorporeal Blood Circulation of a Sheep,” Sensors and Actuators B, vol. 2, pp. 257-263 (1990).
Preidel et al., “In Vitro Measurements with Electrocatalytic Glucose Sensor in Blood,” Biomed. Biochim. Acta, vol. 48, (1989), pp. 897-903.
Richard F. Taylor et al., “An Acetylcholine Receptor-Based Biosensor for the Detection of Cholinergic Agents”, Analytica Chimica Acta, 1988, pgs. 131-138.
Saeger et al., “Influence of Urea on the Glucose Measurement by Electrocatalytic Sensor in Extracorporeal Blood Circulation of a Shee,” Biomed. Biochim. Acta, vol. 50, (1991), 885-891.
Sigma, Hepes Free Acid Product Information, 1996, pp. 1-3.
Singhal, P. et al, Analytical Chemistry 1997, 69, 1662-1668.
Skladal, “Compensation of Temperature Variations Disturbing Performance of an Amperometric Biosensor for Continuous Monitoring,” Sensors and actuators B, Elsevier Sequoia S.A., Lausanne, Ch, vol. 28, No. 1, Jul. 1, 1995, pp. 59-62, XP004004390, ISSN: 0925-4005.
T. Boltshauser et al., “Capacitive Humidity Sensors in SACMOS Technology with Moisture Absorbing Photosensitive Polyimide”, Sensors and Actuators, 1991, pp. 509-512.
Talbott, et al., “A New Microchemical Approach to Amperometric Analysis,” Microchemical Journal, vol. 37, (1988), pp. 5-12.
Tender et al., “Electrochemical Patterning of Self-Assembled Monolayers onto Microscopic Arrays of Gold Electrodes Fabricated by Laser Ablation,” American Chemical Society, Langmuir, vol. 12, No. 23, (1996), pp. 5515-5518
Tender, L. et al., Electrochemical Patterning of Self-Assembled Monolayers onto Microscopic Arrays of Gold Electrodes Fabricated by Laser Ablation, Langmuir, 1996, 12, 5515-5518.
Tjin, S.C. et al, Medical and Biological Engineering and Computing, 1998,36,467-470.
Tsutomu Horiuchi et al., “Limiting Current Enhancement by Self-Induced Redox Cycling on a Micro-Macro Twin Electrode”, Journal of the Electrochemical Society, Dec. 1991, pp. 3549-3553, vol. 138, No. 12.
U.S. Appl. No. 10/871,843 Final Office Action mailed Oct. 30, 2009.
Vasile V. Cosofret et al., “Microfabricated Sensor Arrays Sensitive to pH and K+ for Ionic Distribution Measurements in the Beating Heart”, Analytical Chemistry, May 15, 1995, pp. 1647-1653, vol. 67, No. 10.
Vorburger et al., “In the Rough,” National Institute of Standards and Technology, and Ndubuisi Orji, University of North Carolina, Spie's oe magazine, (2002), pp. 31-34.
W. Preidel et al., “In vitro measurements with electrocatalytic glucose sensor in blood”, Biomed. Biochem Acta, 1989, pp. 897-903.
Williams et al., “Electrochemical-Enzymatic Analysis of Blood Glucose and Lactate,” Analytical Chemistry, vol. 42, No. 1, Jan. 1990, pp. 118-121.
Wollenberger et al., “Interdigitated Array Microelectrodes for the Determination of Enzyme Activities,” Analyst, Jun. 1994, pp. 1245-1249.
Yamakoshi, K.—I. et al, Medical and Biological Engineering and Computing, 1994,32, SUPPL., S99-107.
Yamakoshi, K.I. et al, IEEE Transactions on bio-medical engineering, 1980,27, 156-161.
Yang et al., Marching Velocity of Capillary Meniscuses in Microhanels, IEEE 2002.
Yang et al., Marching Velocity of Capillary Meniscuses in Microchanel, IEEE 2002.
Yang et al., Marching Velocity of Capillary Meniscuses in Microchanels, IEEE 2002.
Ying, C.M. et al., Industrial & Engineering Chemistry Research 2000, 39, 396-407.
Zhao, “Contributions of Suspending Medium to Electrical Impedance of Blood,” Biochimica et Biophysica Acta, vol. 1201, (1994), pp. 179-185.
Zhao, “Electrical Impedamce and Haematocrit of Human Blood Various Anticoagulants,” Physical. Maes., vol. 14, (1993). pp. 299-307.
Lambda Physik Brochure for LPX Series.

Related Publications (1)

	Number	Date	Country
	20130043141 A1	Feb 2013	US

Provisional Applications (2)

	Number	Date	Country
	60480397	Jun 2003	US
	60480298	Jun 2003	US

Divisions (3)

	Number	Date	Country
Parent	13418611	Mar 2012	US
Child	13659163		US
Parent	12650065	Dec 2009	US
Child	13418611		US
Parent	12330757	Dec 2008	US
Child	12505124		US

Continuations (1)

	Number	Date	Country
Parent	10688561	Oct 2003	US
Child	12330757		US

Continuation in Parts (5)

	Number	Date	Country
Parent	10871966	Jun 2004	US
Child	12650065		US
Parent	10871673	Jun 2004	US
Child	12650065		US
Parent	12505124	Jul 2009	US
Child	10871673		US
Parent	11746465	May 2007	US
Child	12650065		US
Parent	10688312	Oct 2003	US
Child	11746465		US

System and method for determining the concentration of an analyte in a sample fluid

Information

Patent Number

Date Filed

Date Issued

Inventors

Original Assignees

Examiners

Agents

CPC

US Classifications

Field of Search

US

International Classifications

Disclaimer

Abstract

Description

Claims

REFERENCE TO RELATED APPLICATIONS

US Referenced Citations (725)

Foreign Referenced Citations (379)

Non-Patent Literature Citations (104)

Related Publications (1)

Provisional Applications (2)

Divisions (3)

Continuations (1)

Continuation in Parts (5)